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IMPORTANCE Kidney disease is a substantial worldwide clinical and public health problem,
but information about available care is limited.
OBJECTIVE To collect information on the current state of readiness, capacity, and
competence for the delivery of kidney care across countries and regions of the world.
DESIGN, SETTING, AND PARTICIPANTS Questionnaire survey administered fromMay to
September 2016 by the International Society of Nephrology (ISN) to 130 ISN-affiliated
countries with sampling of key stakeholders (national nephrology society leadership, policy
makers, and patient organization representatives) identified by the country and regional
nephrology leadership through the ISN.
MAIN OUTCOMES ANDMEASURES Core areas of country capacity and response
for kidney care.
RESULTS Responses were received from 125 of 130 countries (96%), including 289 of 337
individuals (85.8%, with a median of 2 respondents [interquartile range, 1-3]), representing
an estimated 93% (6.8 billion) of the world’s population of 7.3 billion. There was wide
variation in country readiness, capacity, and response in terms of service delivery, financing,
workforce, information systems, and leadership and governance. Overall, 119 (95%), 95
(76%), and 94 (75%) countries had facilities for hemodialysis, peritoneal dialysis, and kidney
transplantation, respectively. In contrast, 33 (94%), 16 (45%), and 12 (34%) countries in
Africa had facilities for hemodialysis, peritoneal dialysis, and kidney transplantation,
respectively. For chronic kidney disease (CKD) monitoring in primary care, serum creatinine
with estimated glomerular filtration rate and proteinuria measurements were reported as
always available in only 21 (18%) and 9 (8%) countries, respectively. Hemodialysis, peritoneal
dialysis, and transplantation services were funded publicly and free at the point of care
delivery in 50 (42%), 48 (51%), and 46 (49%) countries, respectively. The number of
nephrologists was variable and was low (<10 per million population) in Africa, the Middle East,
South Asia, and Oceania and South East Asia (OSEA) regions. Health information system
(renal registry) availability was limited, particularly for acute kidney injury (8 countries [7%])
and nondialysis CKD (9 countries [8%]). International acute kidney injury and CKD guidelines
were reportedly accessible in 52 (45%) and 62 (52%) countries, respectively. There was
relatively low capacity for clinical studies in developing nations.
CONCLUSIONS AND RELEVANCE This survey demonstrated significant interregional and
intraregional variability in the current capacity for kidney care across the world, including
important gaps in services and workforce. Assuming the responses accurately reflect the
status of kidney care in the respondent countries, the findings may be useful to inform efforts
to improve the quality of kidney care worldwide.
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K
idney disease is a substantial worldwide clinical and
public health problem.1-3 Acute kidney injury (AKI)
and chronic kidney disease (CKD) are linked to high
health care costs, poor quality of life, and serious adverse
health outcomes (including cardiovascular disease, kidney
failure requiring kidney replacement therapy, infection,
depression, and mortality).3-7 However, despite the burden
and population health effect of kidney diseases, AKI and CKD
are often not included in the major chronic disease control
strategies. As an example, the World Health Organization’s
(WHO’s) Global Status Report on Noncommunicable Diseases
20148 makes almost no mention of kidney disease. This pre-
sents an obstacle for engaging with various governments in
addressing AKI and CKD.
The Closing the Gaps initiative is led by the Interna-
tional Society of Nephrology (ISN) and aims to define the
current state of kidney care (for AKI and CKD) worldwide,
including policy recommendations for improvement. As
part of this initiative, a global survey, the Global Kidney
Health Atlas (GKHA) Project, was conducted to collect in-
formation on the current state of readiness, capacity, and




The GKHA Project was a multinational survey conducted by
the ISN to assess current capacity for kidney care across the
world. The survey was administered electronically to indi-
viduals in 130 countries with ISN affiliate societies through
the ISN’s 10 regional boards (Africa, Central and Eastern
Europe, Latin America, Middle East, North America, North
and East Asia, Oceania and South East Asia [OSEA], newly
independent states and Russia, South Asia, and Western
Europe). The project was approved by the University of
Alberta Research Ethics Committee (protocol number
PRO00063121). All individual participants provided written
informed consent.
Purposive sampling was undertaken to include at least 3
key stakeholders per country (national nephrology society
leadership, health policy makers, and patient organization/
foundation/advocacy representatives), each of whom was
identified as being knowledgeable about their country’s kid-
ney care status and nominated by the country and regional
nephrology leadership through the ISN. In some cases, coun-
try stakeholders had a dual role (eg, both nephrology leader
and policy maker) or particular stakeholders (eg, consumer
organization representative) were unable to be identified,
such that some countries were represented by fewer than 3
key stakeholders. The key representatives were sent a letter
of invitation to participate that included a link to the survey’s
online portal (an electronic questionnaire via SurveyMonkey
[https://www.surveymonkey.com/]). Respondents were
asked specifically about important within-country heteroge-
neity on kidney care funding and delivery and to identify
other potential key respondents, increasing the likelihood
that relevant information would be widely captured. The sur-
vey was conducted fromMay to September 2016. During this
period, follow-up was conducted by email and telephone to
ISN regional leaders and country leadership to facilitate
completion and timely responses. During the survey period,
each survey respondent who had not yet returned their sur-
vey received a personalized email reminder every 2 to 3
weeks up to a maximum of 3 attempts.
Development and Validation of Survey Instrument
The design of the GKHA questionnaire was meant to col-
lect information about nations’ capacities and responses
about noncommunicable disease prevention and control.
The survey development process considered a number of
documents, including WHO’s Universal Health Coverage:
Supporting Country Needs, the ISN’s AKI “0 by 25” project,
WHO Noncommunicable Disease Surveys (2000, 2005, 2010,
and 2013), the World Heart Federation’s “25 by 25” goal, the
International Diabetes Federation’s Global Diabetes Atlas,
and WHO’s Global Atlas on Cardiovascular Disease Preven-
tion and Control, as well as multiple United Nations policy
documents on strategies, and policies for noncommuni-
cable diseases.9-14 The initial survey questions were further
developed through a series of reviews with relevant experts,
the ISN Executive Committee, and regional leaderships.
The questionnaire was reviewed by the GKHA steering
committee (scientific experts) and ISN regional leaders for
content validity and comprehensiveness. The questionnaire
was piloted across the 10 ISN regional board memberships
to identify any logistical and feasibility issues (eg, need for
translation). The format and content of the questionnaire
(eAppendix 1 in the Supplement) were finalized based on
feedback and identified issues, including translating the
original English-language survey instrument into French
and Spanish by certified translators. The French and Span-
ish surveys were checked by relevant regional boards and
were back-translated into English.
The questionnaire was designed in 2 sections that
addressed the core areas of country and regional capacity
for kidney care delivery. The first section comprised 6 mod-
ules assessing country and regional profile for readiness,
Key Points
Question What is the status of kidney health care across
the world?
Findings In a survey of 125 (96%) of 130 International Society of
Nephrology–affiliated countries (representing an estimated 93%
of the world’s population) with a response rate of 85.8% (289 of
337 individuals surveyed), the findings identified major variation in
reported service delivery, fundingmechanisms for kidney
replacement therapy, and available technologies, such as facilities
for kidney disease detection andmanagement (eg, serum
creatinine and proteinuria assessments).
Meaning These findings on the status of global kidney care may
inform efforts by governmental and nongovernmental groups to
improve the quality of kidney care worldwide.
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Overall 200 7248 130 6778 125 (96) 6754 99.6 93
ISN regions
Africa 54 1156 37 969 35 (95) 964 99 83
Middle East 14 225 13 223 13 (100) 223 100 99
Latin America 25 608 18 571 17 (94) 560 98 92
North and East Asia 7 1602 6 1577 6 (100) 1577 100 98
South Asia 8 1707 5 1673 5 (100) 1673 100 98
OSEA 25 671 13 661 13 (100) 661 100 99
East and Central Europe 20 209 19 207 17 (89) 199 96 95
NIS and Russia 11 281 6 223 6 (100) 223 100 79
Western Europe 22 429 11 318 11 (100) 318 100 74
North America 14 362 2 356 2 (100) 356 100 398
World Bank income groups
Low 31 631 18 405 18 (100) 405 100 64
Lower middle 52 2862 35 2789 34 (97) 2786 99.9 97
Upper middle 53 2370 35 2313 32 (91) 2293 99 97
High 63 1386 41 1271 40 (98) 1270 99.9 92
Not classified 1 0.02 1 0.02 1 (100) 0.02 100 100
Abbreviations: ISN, International Society of Nephrology; NIS, newly
independent states; OSEA, Oceania and South East Asia; UN, United Nations.
a The percentage was calculated as total No. of countries that completed the
survey/total No. of countries that received the survey.
bThe proportion was calculated as total population for countries that
completed the survey/total population for countries that received the survey.
c The proportion was calculated as total population for countries that
completed the survey/total population in all UN-recognized countries.






Respondent Affiliation, No. (%)
Nephrologists Other Physicians Administrators/Policy Makers Otherb
Overall 289d 2 (1-3) 247 (85) 10 (3) 16 (6) 16 (6)
ISN regions
Africa 58 1 (1-2) 42 (73) 4 (7) 6 (10) 6 (10)
Middle East 32 3 (2-3) 29 (91) 1 (3) 1 (3) 1 (3)
Latin America 50 2 (1-3) 50 (100) 0 0 0
North and East Asia 31 6 (2-8) 29 (94) 0 1 (3) 1 (3)
South Asia 12 2 (2-3) 10 (84) 1 (8) 1 (8) 0
OSEA 39 2 (1-4) 31 (79) 2 (5) 3 (8) 3 (8)
East and Central Europe 27 1 (1-2) 26 (96) 1 (4) 0 0
NIS and Russia 12 1.5 (1-2) 7 (59) 0 4 (33) 1 (8)
Western Europe 21 2 (1-3) 17 (81) 1 (5) 0 3 (14)
North America 7 3.5 (3-4) 6 (86) 0 0 1 (14)
World Bank income groups
Low 30 2 (1-2) 22 (73) 4 (13) 2 (7) 2 (7)
Lower middle 68 2 (1-3) 50 (73) 4 (6) 10 (15) 4 (6)
Upper middle 83 2 (1-3) 76 (92) 1 (1) 4 (5) 2 (2)
High 107 2 (1-3.5) 98 (92) 1 (1) 0 8 (7)
Not classified 1 1 (1-1) 1 (100) 0 0 0
Abbreviations: ISN, International Society of Nephrology; NIS, newly
independent states; OSEA, Oceania and South East Asia.
a Total number of respondents to the survey, overall and by ISN regions and
World Bank income groups.
bOther types of stakeholders (eg, nurses, community health officers).
c Median and interquartile range of respondents per country.
dOverall number of individual respondents among 337 contacted (individual
response rate of 85.8%).
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capacity, and response to CKD and AKI premised on the 6
health system building blocks (access to essential medicines
and technologies, health systems financing, health service
delivery, health workforce, health information systems, and
leadership and governance).15 The second section contained
questions that assessed response of the nephrology com-
munity (including care guidelines, position papers, service
frameworks, and advocacy initiatives) and capacity for
research and development.
Data Handling, Analysis, and Reporting
To facilitate data collation, responses to the French and
Spanish surveys were first converted to English by certified
translators. Data from all individual questionnaires were
subsequently automatically extracted and checked for
inconsistencies, missing data, duplications, and formatting
errors. The data were then merged into a single file to create
the global database. This was housed in a secured central-
ized computer system with automated backups.
Liaison with ISN regional leaders was undertaken to
ensure that collated data were consistent with their under-
standing and were of high quality. Each of 10 regional
boards reviewed their output to clarify any ambiguity or
inconsistencies. Any major inconsistencies that remained
following the reviews were systematically addressed
by follow-up of individuals who responded to the survey.
Figure 1. Global Prevalence of Treated End-Stage Renal Disease Per 1 Million Population
Prevalence of treated end-stage






Did not receive survey
International Society of Nephrology regions
Africa




North and East Asia
Oceania and South East Asia
Newly independent states and Russia
South Asia
Western Europe
Themap depicts the prevalence of treated kidney failure per 1 million population based on individual country data. Data not available indicates that data were either
not known or not provided on the questionnaire for countries that received the survey.
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No. (%) of Responding Countries
Publicly Funded
by Government Free
at the Point of Delivery
Publicly Funded
by Government
But With Some Fees














Overall 118 50 (42) 14 (12) 41 (35) 2 (2) 0 11 (9)
ISN regions
Africa 33 10 (30) 7 (21) 12 (37) 1 (3) 0 3 (9)
Middle East 13 9 (69) 1 (8) 1 (8) 0 0 2 (15)
Latin America 15 3 (20) 0 11 (73) 0 0 1 (7)
North and East Asia 6 0 3 (50) 2 (33) 0 0 1 (17)
South Asia 5 0 1 (20) 3 (60) 0 0 1 (20)
OSEA 13 1 (8) 2 (15) 7 (54) 1 (8) 0 2 (15)
East and Central Europe 16 14 (87) 0 2 (13) 0 0 0
NIS and Russia 6 4 (66) 0 1 (17) 0 0 1 (17)
Western Europe 9 7 (78) 0 2 (22) 0 0 0
North America 2 2 (100) 0 0 0 0 0
World Bank income groups
Low 17 3 (18)b 4 (24) 6 (34) 2 (12) 0 2 (12)
Lower middle 32 7 (21) 6 (19) 14 (44) 0 0 5 (16)
Upper middle 31 18 (59) 0 11 (35) 0 0 2 (6)
High 38 22 (58) 4 (11) 10 (26) 0 0 2 (5)
Peritoneal Dialysis
Overall 95 48 (51) 11 (12) 28 (29) 1 (1) 0 7 (7)
ISN regions
Africa 17 6 (35) 4 (24) 6 (35) 0 0 1 (6)
Middle East 11 7 (64) 2 (18) 0 1 (9) 0 1 (9)
Latin America 15 4 (27) 0 11 (73) 0 0 0
North and East Asia 6 0 4 (66) 1 (17) 0 0 1 (17)
South Asia 5 1 (20) 1 (20) 2 (40) 0 0 1 (20)
OSEA 9 1 (11) 0 6 (67) 0 0 2 (22)
East and Central Europe 15 14 (93) 0 1 (7) 0 0 0
NIS and Russia 6 5 (83) 0 0 0 0 1 (17)
Western Europe 9 8 (89) 0 1 (11) 0 0 0
North America 2 2 (100) 0 0 0 0 0
World Bank income groups
Low 6 0 2 (33) 3 (50) 0 0 1 (17)
Lower middle 22 6 (27) 3 (14) 10 (45) 1 (5) 0 2 (9)
Upper middle 29 17 (58) 2 (7) 8 (28) 0 0 2 (7)
High 38 25 (66) 4 (11) 7 (18) 0 0 2 (5)
Kidney Transplantation
Overall 93 46 (49) 10 (11) 28 (30) 1 (1) 0 8 (9)
ISN regions
Africa 12 4 (33) 1 (8) 4 (33) 1 (8) 0 2 (18)
Middle East 13 6 (46) 4 (31) 0 0 0 3 (23)
Latin America 15 2 (13) 0 12 (80) 0 0 1 (7)
North and East Asia 6 0 5 (83) 0 0 0 1 (17)
South Asia 5 0 0 5 (100) 0 0 0
OSEA 9 3 (33) 0 5 (56) 0 0 1 (11)
East and Central Europe 16 16 (100) 0 0 0 0 0
NIS and Russia 6 5 (83) 0 1 (17) 0 0 0
Western Europe 9 8 (89) 0 1 (11) 0 0 0
North America 2 2 (100) 0 0 0 0 0
(continued)
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Further validation was carried out at country and regional
levels by triangulation of the findings with published litera-
ture and other sources of information (government reports
and other sources provided by the survey respondents). For
example, among the responses for New Zealand, 2 indicated
that there was an official registry for dialysis and transplan-
tation, whereas 1 indicated that there was not an official reg-
istry. The existence of a New Zealand dialysis registry was
subsequently confirmed by cross-checking with the OSEA
Regional Board and the Australian and New Zealand Dialysis
and Transplant Registry (http://www.anzdata.org.au/).
Similarly, 2 Kenyan respondents indicated that there was
anephrology trainingprograminKenya,whereas 1 respondent
said there was not a nephrology training program but also
indicated only moderate certainty of the answer. Telephone
discussion with the African Regional Board confirmed that
a nephrology training program did exist in Kenya.
The framework developed by WHO (Assessing National
Capacity for the Prevention and Control of Noncommuni-
cable Diseases) was leveraged in the approach to the statisti-
cal analysis of the collated data.16 The analysis was con-
ducted using Stata version 13 software (Stata Corp). The unit
of analysis was responding country, and results were strati-
fied by ISN region (n = 10) andWorld Bank country classifica-
tion (n = 4) as low-, lower middle–, upper middle–, and high-
income nations. Responses were summarized based on the
key questionnaire domains using a descriptive statistical
approach and reported as counts and percentages or medians
and interquartile ranges, as appropriate. Nonquantitative
data (text response items of the questionnaire) were themati-
cally analyzed using a standard approach.17 The results were
examined with an emphasis on identification of key gaps
and challenges across the various domains based on the pre-
existing protocol and reported according to the Guidelines




Responses were received from 125 (96%) of 130 countries,
including 289 (85.8%) of 337 individuals (median of 2
respondents per country [interquartile range, 1-3]) repre-
senting an estimated 93% (6.8 billion) of the world’s popula-
tion of 7.3 billion (Table 1). Responses were received from
100% (18/18), 97% (34/35), 91% (32/35), and 98% (40/41) of
low-income, lower middle–income, upper middle–income,
and high-income countries, respectively (Table 1). The
respondent countries were representative of the countries
in each region by population size (Table 1). The survey
respondents consisted of nephrologists (247 [85%]), other
physicians (10 [3%]), administrators/policy makers
(16 [6%]), and others (16 [6%]) affiliated with kidney disease
patient advocacy (Table 2).
Country Readiness, Capacity, and Response to CKD and AKI
Access to Essential Medicines and Technologies
There were variations across ISN regions (n = 10) and World
Bank income groups (n = 4) in the prevalence of treated
end-stage renal disease represented by kidney replacement
therapy (kidney replacement therapy: hemodialysis, perito-
neal dialysis, and kidney transplantation), with the highest
prevalence in developed regions in comparison with devel-
oping nations (Figure 1). The reported availability and
access to essential medicines for CKD care and technologies
also showed significant variations across regions and coun-
tries (eAppendix 2 in the Supplement). Among all countries
(n=125 responding), 119 (95%), 95 (76%), and 94 (75%) had
facilities for hemodialysis, long-term peritoneal dialysis,
and kidney transplantation, respectively; 100% of high-
income countries had such facilities. In contrast, 33 (94%),
16 (45%), and 12 (34%) countries in Africa had facilities for
hemodialysis, long-term peritoneal dialysis, and kidney
transplantation, respectively (eAppendix 2).
Health Systems Financing
The number of countries (n=118 responding) that reported
complete public funding (completely free care at the point
of delivery covered by the government) for chronic hemodi-
alysis, long-term peritoneal dialysis, and kidney trans-
plantation were 50 (42%), 48 (51%), and 46 (49%), respec-
tively (Table 3). Overall, 45 (39%) and 34 (49%) countries
reported complete public funding for hemodialysis and
peritoneal dialysis, respectively, in the acute setting
(Table 4). The public funding structures for all forms of




No. (%) of Responding Countries
Publicly Funded
by Government Free
at the Point of Delivery
Publicly Funded
by Government
But With Some Fees













World Bank income groups
Low 2 1 (50) 0 1 (50) 0 0 0
Lower middle 24 4 (17) 3 (13) 13 (53) 1 (4) 0 3 (13)
Upper middle 29 15 (52) 2 (7) 9 (31) 0 0 3 (10)
High 38 26 (69) 5 (13) 5 (13) 0 0 2 (5)
Abbreviations: ISN, International Society of Nephrology; NIS, newly
independent states; OSEA, Oceania and South East Asia.
a Involving government, nongovernmental organizations, and communities.
bLow-income countries offering long-term hemodialysis free of cost were Chad,
Gambia, and Guinea.
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kidney replacement therapy (hemodialysis, peritoneal
dialysis, and kidney transplantation) were less common in
the low- and lower middle–income countries (Table 3 and
Table 4). There was significant variation across regions in
access to medications for kidney care. For instance, no
country from the low-income and lower middle–income cat-
egories reported complete public funding for medications
for nondialysis CKD care (including angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers, other
antihypertensive agents, statins, and glucose-lowering
agents) (Table 5 and eAppendix 2 in the Supplement). In
contrast, 12 (32%) and 10 (32%) high- and upper middle–
income nations reported complete public funding for medi-
cations in nondialysis CKD care (Table 5).
Health Service Delivery
Globally, infrastructure available for kidney care was re-
ported to be good/above average in 48 (39%) and excellent in
11 (9%) countries for AKI. For CKD, 46 (38%) countries were
rated good/above average and 9 (7%) were rated excellent




No. (%) of Responding Countries
Publicly Funded
by Government Free
at the Point of Delivery
Publicly Funded
by Government
But With Some Fees














Overall 116 45 (39) 22 (19) 41 (35) 1 (1) 0 7 (6)
ISN regions
Africa 32 10 (32) 9 (28) 9 (28) 1 (3) 0 3 (9)
Middle East 13 6 (46) 1 (8) 4 (31) 0 0 2 (15)
Latin America 15 2 (13) 0 13 (87) 0 0 0
North and East Asia 6 0 4 (66) 1 (17) 0 0 1 (17)
South Asia 5 0 1 (20) 4 (80) 0 0 0
OSEA 13 2 (15) 4 (31) 6 (46) 0 0 1 (8)
East and Central Europe 16 14 (88) 1 (6) 1 (6) 0 0 0
NIS and Russia 5 3 (60) 1 (20) 1 (20) 0 0 0
Western Europe 9 7 (78) 1 (11) 1 (11) 0 0 0
North America 2 1 (50) 0 1 (50) 0 0 0
World Bank income groups
Low 16 4 (25)b 5 (32) 5 (31) 1 (6) 0 1 (6)
Lower middle 32 5 (16) 10 (31) 14 (44) 0 0 3 (9)
Upper middle 30 16 (53) 1 (3) 11 (37) 0 0 2 (7)
High 38 20 (52) 6 (16) 11 (29) 0 0 1 (3)
Acute Peritoneal Dialysis
Overall 70 34 (49) 11 (16) 19 (27) 3 (4) 0 3 (4)
ISN regions
Africa 11 3 (27) 2 (18) 4 (37) 1 (9) 0 1 (9)
Middle East 7 5 (72) 1 (14) 0 0 0 1 (14)
Latin America 14 4 (29) 1 (7) 7 (50) 2 (14) 0 0
North and East Asia 4 0 4 (100) 0 0 0 0
South Asia 5 1 (20) 0 4 (80) 0 0 0
OSEA 6 1 (17) 2 (33) 2 (33) 0 0 1 (17)
East and Central Europe 11 10 (91) 1 (9) 0 0 0 0
NIS and Russia 4 4 (100) 0 0 0 0 0
Western Europe 6 5 (83) 0 1 (17) 0 0 0
North America 2 1 (50) 0 1 (50) 0 0 0
World Bank income groups
Low 4 0 0 3 (75) 1 (25) 0 0
Lower middle 17 7 (41) 3 (18) 5 (29) 0 0 2 (12)
Upper middle 22 13 (59) 2 (9) 6 (27) 1 (5) 0 0
High 27 14 (51) 6 (22) 5 (19) 1 (4) 0 1 (4)
Abbreviations: ISN, International Society of Nephrology; NIS, newly
independent states; OSEA, Oceania and South East Asia.
a Involving government, nongovernmental organizations, and communities.
bLow-income countries offering acute hemodialysis free of cost were Chad,
Gambia, Mozambique, and Tanzania.
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No. (%) of Responding Countries
Publicly Funded
by Government Free
at the Point of Delivery
Publicly Funded
by Government
But With Some Fees













Nondialysis Chronic Kidney Disease
Overall 118 22 (19) 22 (19) 51 (42) 9 (8) 1 (1) 13 (11)
ISN regions
Africa 32 1 (3) 8 (25) 12 (37) 6 (19) 0 5 (16)
Middle East 13 3 (23) 2 (15) 5 (39) 1 (8) 0 2 (15)
Latin America 16 2 (13) 0 12 (75) 0 1 (6) 1 (6)
North and East Asia 6 1 (17) 2 (33) 2 (33) 0 0 1 (17)
South Asia 5 0 0 4 (80) 0 0 1 (20)
OSEA 13 1 (8) 2 (15) 8 (62) 2 (15) 0 0
East and Central Europe 16 11 (69) 4 (25) 1 (6) 0 0 0
NIS and Russia 6 1 (17) 0 3 (50) 0 0 2 (33)
Western Europe 9 2 (22) 4 (45) 2 (22) 0 0 1 (11)
North America 2 0 0 2 (100) 0 0 0
World Bank income groups
Low 17 0 3 (18) 5 (29) 5 (29) 0 4 (24)
Lower middle 32 0 7 (22) 15 (46) 4 (13) 1 (3) 5 (16)
Upper middle 31 10 (32) 2 (6) 17 (56) 0 0 2 (6)
High 38 12 (32) 10 (26) 14 (37) 0 0 2 (5)
Dialysis
Overall 118 26 (22) 29 (25) 46 (38) 8 (7) 1 (1) 8 (7)
ISN regions
Africa 32 2 (6) 9 (28) 11 (34) 6 (19) 0 4 (13)
Middle East 13 5 (39) 4 (31) 2 (15) 0 0 2 (15)
Latin America 16 3 (19) 0 12 (75) 0 1 (6) 0
North and East Asia 6 0 3 (50) 2 (33) 0 0 1 (17)
South Asia 5 0 0 4 (80) 1 (20) 0 0
OSEA 13 0 4 (30) 8 (62) 1 (8) 0 0
East and Central Europe 16 12 (75) 4 (25) 0 0 0 0
NIS and Russia 6 1 (17) 0 4 (66) 0 0 1 (17)
Western Europe 9 3 (33) 5 (56) 1 (11) 0 0 0
North America 2 0 0 2 (100) 0 0 0
World Bank income groups
Low 17 0 4 (24) 6 (35) 5 (29) 0 2 (12)
Lower middle 32 0 7 (22) 18 (57) 3 (9) 1 (3) 3 (9)
Upper middle 31 13 (42) 4 (13) 12 (39) 0 0 2 (6)
High 38 13 (34) 14 (37) 10 (26) 0 0 1 (3)
Kidney Transplantation
Overall 118 35 (30) 22 (18) 35 (30) 18 (15) 1 (1) 7 (6)
ISN regions
Africa 32 5 (16) 3 (9) 6 (19) 14 (43) 0 4 (13)
Middle East 13 7 (54) 3 (23) 0 0 0 3 (23)
Latin America 16 4 (25) 0 11 (69) 0 1 (6) 0
North and East Asia 6 0 3 (50) 3 (50) 0 0 0
South Asia 5 0 0 4 (80) 1 (20) 0 0
OSEA 13 1 (8) 2 (15) 7 (54) 3 (23) 0 0
East and Central Europe 16 13 (81) 3 (19) 0 0 0 0
NIS and Russia 6 4 (66) 1 (17) 1 (17) 0 0 0
Western Europe 9 1 (11) 7 (78) 1 (11) 0 0 0
North America 2 0 0 2 (100) 0 0 0
(continued)
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(eTable 1 in the Supplement). Reports of extremely poor or
poor/belowaverage infrastructure for AKI andCKDcarewere
highest inAfrica andSouthAsia and lowest inWesternEurope
and North America (eTable 1). Pertaining to services used for
monitoring CKD, measurement of serum creatinine reported
with estimated glomerular filtration rate (eGFR) was de-
scribed as always or usually available at the primary and sec-
ondary care levels in only 21 (18%) or 23 (19%) and 43 (40%)
or 25 (23%) countries, respectively (Table 6,Table 7, and eAp-
pendix 3 in the Supplement). Pathological services for renal
biopsy were always available at the secondary care level for
27 (23%) countries but were otherwise rarely or never avail-
able in 28 (24%) and 16 (14%) countries, respectively (Table 7
and eAppendix 3).
HealthWorkforce
Respondents from countries were asked to provide esti-
mates of the number of trained nephrologists, as defined by
the relevant regulatory authorities, and provide an opinion
regarding shortage (yes/no) of the workforce required for
kidney care delivery. There was a low reported nephrology
workforce density (≤10 per 1 million population) for several
countries in the Africa, North and East Asia, and South Asia
regions as well as in parts of Latin America (Figure 2). There
were also wide disparities in the number of nephrologists
across countries and regions. For instance, 9 of the 10 coun-
tries with the lowest numbers of nephrologists were in sub-
Saharan Africa (eFigure 1A in the Supplement), whereas the
countries with the highest number of nephrologists were
from several regions, with Lithuania, Taiwan, and Japan
reporting the highest numbers of nephrologists per 1 million
population (eFigure 1B in the Supplement). Overall, there
were frequent reported shortages of the various categories
of other health care workers. Most countries had reported
shortages of vascular access coordinators, transplant coordi-
nators, social workers, renal pathologists, nurse practition-
ers, nephrologists, dieticians, dialysis technicians, dialysis
nurses, and counselors and psychologists (Figure 2C).
In contrast, fewer countries reported shortages of pharma-
cists, laboratory technicians, and primary care physicians
(Figure 2C). By region, shortages of other health care clini-
cians were more common in Africa, the Middle East,
Latin America, South Asia, North and East Asia, OSEA, and
East and Central Europe (eTable 2 in the Supplement). For
example, 28 (85%) countries in Africa had reported short-
ages of nephrologists compared with only 2 (20%) countries
in Western Europe with reported shortages of this category
of workforce (eTable 2).
Health Information Systems
Countries were asked to provide data on the availability of
registries (surveillance and monitoring systems) for kidney
replacement therapy and nondialysis CKD and AKI. The
prevalence of treated end-stage renal disease was compara-
tively low in some regions compared with others (Figure 1).
For instance, Africa, the Middle East, and South Asia had
low prevalence of treated end-stage renal disease in com-
parison with North America and Western Europe (where the
prevalence was generally above 1000 per 1 million popula-
tion) (Figure 1). Overall, only 9 (7.7%) and 8 (6.8%) countries
reported having registries for nondialysis CKD and AKI,
respectively (eFigure 2 and eAppendix 3 in the Supple-
ment). There was wide variation in the presence of kidney
replacement therapy registries across regions, with most
countries reporting having dialysis registries and fewer
reporting having kidney transplant registries, particularly in
Africa, the Middle East, and South Asia (eFigure 2 and eAp-
pendix 3). Dialysis and kidney transplant registries were
most commonly available in Western Europe, North and
East Asia, North America, and East and Central European
countries (eFigure 2 and eAppendix 3).
Leadership and Governance
Specific national strategies for improving the care of
patients with CKD were reported as present in only 19 coun-
tries (17%) (eTable 3 in the Supplement). There were varia-
tions in the availability of 1 or more of the various strategies
(national position paper, identification tools, incentives,
etc) for improving identification of AKI across regions;
59 countries (51%) had none of these strategies (eTable 4 in
the Supplement).
Response of the Nephrology Community
(Guidelines and Advocacy for Kidney Care)
The majority of countries reported access predominantly to
international guidelines compared with national guidelines.




No. (%) of Responding Countries
Publicly Funded
by Government Free
at the Point of Delivery
Publicly Funded
by Government
But With Some Fees













World Bank income groups
Low 17 0 1 (6) 3 (18) 10 (58) 0 3 (18)
Lower middle 32 6 (19) 4 (13) 12 (37) 7 (22) 1 (3) 2 (6)
Upper middle 31 15 (49) 3 (10) 11 (35) 1 (3) 0 1 (3)
High 38 14 (37) 14 (37) 9 (23) 0 0 1 (3)
Abbreviations: ISN, International Society of Nephrology; NIS, newly independent states; OSEA, Oceania and South East Asia.
a Involving government, nongovernmental organizations, and communities.
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Table 6. Availability of Services for Chronic Kidney DiseaseMonitoring andManagement
at Primary Care Level
No. of
Responding Countries
Availability, No. (%) of Responding Countries
Always Usually Rarely Never
Blood Pressure
Overall 119 75 (63) 40 (34) 4 (3) 0
ISN regions
Africa 33 15 (45) 16 (49) 2 (6) 0
Middle East 13 9 (70) 2 (15) 2 (15) 0
Latin America 16 12 (75) 4 (25) 0 0
North and East
Asia
6 1 (17) 5 (83) 0 0
South Asia 5 3 (60) 2 (40) 0 0
OSEA 13 8 (62) 5 (38) 0 0
East and Central
Europe
16 14 (87) 2 (13) 0 0
NIS and Russia 6 4 (67) 2 (33) 0 0
Western Europe 9 7 (78) 2 (22) 0 0
North America 2 2 (100) 0 0 0
World Bank income groups
Low 17 8 (47) 8 (47) 1 (6) 0
Lower middle 33 16 (49) 15 (45) 2 (6) 0
Upper middle 31 23 (74) 8 (26) 0 0
High 38 28 (73) 9 (24) 1 (3) 0
Blood Glucose
Overall 119 48 (40) 50 (42) 19 (16) 2 (2)
ISN regions
Africa 33 9 (27) 10 (30) 12 (37) 2 (6)
Middle East 13 6 (46) 6 (46) 1 (8) 0
Latin America 16 7 (44) 7 (44) 2 (12) 0
North and East
Asia
6 0 6 (100) 0 0
South Asia 5 1 (20) 2 (40) 2 (40) 0
OSEA 13 4 (31) 8 (61) 1 (8) 0
East and Central
Europe
16 10 (63) 5 (31) 1 (6) 0
NIS and Russia 6 2 (33) 4 (67) 0 0
Western Europe 9 8 (89) 1 (11) 0 0
North America 2 1 (50) 1 (50) 0 0
World Bank income groups
Low 17 4 (24) 3 (18) 8 (46) 2 (12)
Lower middle 33 9 (27) 16 (49) 8 (24) 0
Upper middle 31 12 (39) 17 (55) 2 (6) 0
High 38 23 (60) 14 (37) 1 (3) 0
Serum Creatinine
Serum creatinine with eGFR reporting
Overall 119 21 (18) 23 (19) 48 (40) 27 (23)
ISN regions
Africa 33 1 (3) 4 (12) 15 (46) 13 (39)
Middle East 13 1 (8) 3 (23) 7 (54) 2 (15)
Latin America 16 2 (13) 4 (25) 7 (43) 3 (19)
North and East
Asia
6 0 2 (33) 3 (50) 1 (17)
South Asia 5 1 (20) 0 3 (60) 1 (20)
OSEA 13 2 (15) 3 (23) 6 (47) 2 (15)
East and Central
Europe
16 8 (49) 3 (19) 3 (19) 2 (13)
NIS and Russia 6 0 1 (17) 2 (33) 3 (50)
Western Europe 9 5 (56) 2 (22) 2 (22) 0
North America 2 1 (50) 1 (50) 0 0
(continued)
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Table 6. Availability of Services for Chronic Kidney DiseaseMonitoring andManagement
at Primary Care Level (continued)
No. of
Responding Countries
Availability, No. (%) of Responding Countries
Always Usually Rarely Never
World Bank income groups
Low 17 0 0 7 (41) 10 (59)
Lower middle 33 3 (9) 2 (6) 18 (55) 10 (30)
Upper middle 31 4 (13) 9 (29) 12 (39) 6 (19)
High 38 14 (36) 12 (32) 11 (29) 1 (3)
Serum creatinine without eGFR reporting
Overall 119 31 (26) 46 (39) 32 (27) 10 (8)
ISN regions
Africa 33 5 (15) 10 (30) 12 (37) 6 (18)
Middle East 13 5 (38) 5 (38) 3 (24) 0
Latin America 16 4 (25) 9 (56) 3 (19) 0
North and East Asia 6 0 5 (83) 1 (17) 0
South Asia 5 1 (20) 1 (20) 2 (40) 1 (20)
OSEA 13 3 (23) 3 (23) 5 (39) 2 (15)
East and Central Europe 16 7 (44) 4 (25) 4 (25) 1 (6)
NIS and Russia 6 1 (17) 5 (83) 0 0
Western Europe 9 5 (56) 2 (22) 2 (22) 0
North America 2 0 2 (100) 0 0
World Bank income groups
Low 17 1 (6) 4 (24) 5 (29) 7 (41)
Lower middle 33 5 (15) 13 (40) 13 (39) 2 (6)
Upper middle 31 9 (29) 18 (58) 4 (13) 0
High 38 16 (42) 11 (29) 10 (26) 1 (3)
Radiology Services
Overall 119 17 (14) 38 (32) 48 (41) 16 (13)
ISN regions
Africa 33 5 (15) 5 (15) 14 (43) 9 (27)
Middle East 13 1 (8) 3 (23) 6 (46) 3 (23)
Latin America 16 3 (19) 3 (19) 9 (56) 1 (6)
North and East Asia 6 1 (17) 1 (17) 4 (66) 0
South Asia 5 1 (20) 1 (20) 3 (60) 0
OSEA 13 0 6 (46) 6 (46) 1 (8)
East and Central Europe 16 3 (19) 9 (56) 3 (19) 1 (6)
NIS and Russia 6 1 (17) 3 (50) 2 (33) 0
Western Europe 9 2 (22) 5 (56) 1 (11) 1 (11)
North America 2 0 2 (100) 0 0
World Bank income groups
Low 17 1 (6) 1 (6) 8 (47) 7 (41)
Lower middle 33 4 (12) 8 (24) 18 (55) 3 (9)
Upper middle 31 6 (19) 10 (32) 11 (36) 4 (13)
High 38 6 (16) 19 (50) 11 (29) 2 (5)
Urinalysis (Qualitative Assays)
Overall 119 26 (22) 54 (45) 32 (27) 7 (6)
ISN regions
Africa 33 5 (15) 11 (33) 13 (40) 4 (12)
Middle East 13 2 (15) 10 (77) 1 (8) 0
Latin America 16 3 (19) 6 (38) 6 (37) 1 (6)
North and East Asia 6 0 4 (67) 2 (33) 0
South Asia 5 2 (40) 2 (40) 1 (20) 0
OSEA 13 2 (16) 5 (38) 5 (38) 1 (8)
East and Central Europe 16 7 (44) 7 (44) 1 (6) 1 (6)
NIS and Russia 6 1 (17) 2 (33) 3 (50) 0
Western Europe 9 4 (44) 5 (56) 0 0
North America 2 0 2 (100) 0 0
(continued)
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Access to international CKD and AKI management guide-
lines was reported in 60 (52%) and 52 (45%) countries,
respectively (eTable 5 in the Supplement). Thirty-one coun-
tries (27%) reported availability of national guidelines for
CKD (eTable 5). In contrast, only 8 countries (7%) reported
access to national guidelines for AKI. Presence of CKD and
AKI advocacy groups were limited in most regions and were
more common for CKD than for AKI (eFigure 3 and eAppen-
dix 3 in the Supplement).
Capacity for Research and Development
Respondents rated their involvement with different phases
of clinical trials and observational research studies (avail-
able infrastructure, trained workforce, ethical frameworks,
etc). Low capacity for participation in different aspects of
clinical trials was frequently reported, especially in devel-
oping countries and regions (eAppendix 3 in the Supple-
ment). For example, only 33 (28%) and 46 (40%) countries
overall could participate in phase 1 and phase 2 clinical
trials, respectively (eTable 6 and eAppendix 3 in the Supple-
ment). Western Europe and North America reported the
highest capacity to participate in all phases of clinical trials
(eTable 6 and eAppendix 3). For instance, all countries in
these 2 regions reported capacity to participate in phase 3
and 4 trials in contrast to only 5 (17%) and 4 (13%) in Africa,
respectively (eTable 6). Although most countries described
some capacity to conduct or participate in observational
cohort studies, Africa and Middle East countries reported no
capacity to participate in transplantation cohort studies
(eTable 6). Institutional ethics approval was the most com-
mon study approval type in most countries overall and
across most regions (eTable 6).
Discussion
To our knowledge, this is the first systematic assessment of
the global capacity for kidney care in terms of the key build-
ing blocks of a functional health system and readiness of
countries and regions to enhance such care. There were sig-
nificant gaps reported in services, facilities, and workforce
in some countries and regions. Most countries in Africa
described no facilities for peritoneal dialysis or kidney
transplantation. Few countries reported complete public
funding for kidney replacement therapy services and medi-
cations for CKD care (including dialysis and transplanta-
tion); there was a large private contribution toward payment
for kidney replacement therapy services and medications
reported particularly in countries across the Africa, South
Asia, and OSEA regions. Even though the infrastructure
available for AKI and CKD care was mostly rated as average
or above average, survey responses suggested that measure-
ment of serum creatinine with eGFR was common at the
primary care level in only a few countries. Availability of
pathological services for kidney biopsy was described as
very low. Overall, there was a reported shortage of nephrol-
ogy workforce and other workforce categories in many set-
tings. There was limited availability of health information
systems (renal registries), particularly for nondialysis CKD
and AKI. National or regional strategies for improving CKD
Table 6. Availability of Services for Chronic Kidney DiseaseMonitoring andManagement
at Primary Care Level (continued)
No. of
Responding Countries
Availability, No. (%) of Responding Countries
Always Usually Rarely Never
World Bank income groups
Low 17 3 (18) 4 (24) 7 (41) 3 (18)
Lower middle 33 5 (16) 13 (39) 13 (39) 2 (6)
Upper middle 31 4 (13) 18 (58) 7 (23) 2 (6)
High 38 14 (37) 19 (50) 5 (13) 0
UACR or UPCR Measurement
Overall 119 9 (8) 29 (24) 52 (44) 29 (24)
ISN regions
Africa 33 0 4 (12) 11 (33) 18 (55)
Middle East 13 0 6 (46) 6 (46) 1 (8)
Latin America 16 3 (19) 5 (31) 5 (31) 3 (19)
North and East Asia 6 0 0 6 (100) 0
South Asia 5 0 1 (20) 4 (80) 0
OSEA 13 1 (8) 3 (23) 7 (54) 2 (15)
East and Central Europe 16 2 (13) 2 (13) 9 (55) 3 (19)
NIS and Russia 6 0 1 (17) 3 (50) 2 (33)
Western Europe 9 3 (33) 5 (56) 1 (11) 0
North America 2 0 2 (100) 0 0
World Bank income groups
Low 17 0 0 3 (18) 14 (82)
Lower middle 33 1 (3) 4 (12) 18 (55) 10 (30)
Upper middle 31 3 (10) 8 (26) 16 (51) 4 (13)
High 38 5 (13) 17 (45) 15 (39) 1 (3)
Abbreviations: eGFR, estimated
glomerular filtration rate;
ISN, International Society of
Nephrology; NIS, newly independent
states; OSEA, Oceania and
South East Asia; UACR, urine
albumin:creatinine ratio; UPCR, urine
protein:creatinine ratio.
Assessment of Global Kidney Health Care Status Original Investigation Research
jama.com (Reprinted) JAMA May 9, 2017 Volume 317, Number 18 1875
Copyright 2017 American Medical Association. All rights reserved.
Table 7. Availability of Services for Chronic Kidney DiseaseMonitoring andManagement at Secondary
or Tertiary Care Levels
No. of
Responding Countries
Availability, No. (%) of Responding Countries
Always Usually Rarely Never
Blood Pressure
Overall 119 106 (89) 13 (11) 0 0
ISN regions
Africa 33 27 (82) 6 (18) 0 0
Middle East 13 13 (100) 0 0 0
Latin America 16 15 (94) 1 (6) 0 0
North and East Asia 6 3 (50) 3 (50) 0 0
South Asia 5 5 (100) 0 0 0
OSEA 13 12 (92) 1 (8) 0 0
East and Central Europe 16 16 (100) 0 0 0
NIS and Russia 6 5 (83) 1 (17) 0 0
Western Europe 9 8 (89) 1 (11) 0 0
North America 2 2 (100) 0 0 0
World Bank income groups
Low 17 14 (82) 3 (18) 0 0
Lower middle 33 28 (85) 5 (15) 0 0
Upper middle 31 29 (94) 2 (6) 0 0
High 38 35 (92) 3 (8) 0 0
Blood Glucose
Overall 119 83 (70) 35 (29) 1 (1) 0
ISN regions
Africa 33 18 (55) 14 (42) 1 (3) 0
Middle East 13 12 (92) 1 (8) 0 0
Latin America 16 14 (87) 2 (13) 0 0
North and East Asia 6 1 (17) 5 (83) 0 0
South Asia 5 4 (80) 1 (20) 0 0
OSEA 13 7 (54) 6 (46) 0 0
East and Central Europe 16 15 (94) 1 (6) 0 0
NIS and Russia 6 3 (50) 3 (50) 0 0
Western Europe 9 7 (78) 2 (22) 0 0
North America 2 2 (100) 0 0 0
World Bank income groups
Low 17 10 (59) 7 (41) 0 0
Lower middle 33 17 (52) 15 (45) 1 (3) 0
Upper middle 31 25 (81) 6 (19) 0 0
High 38 31 (82) 7 (18) 0 0
Serum Creatinine
Serum creatinine with eGFR reporting
Overall 108 43 (40) 25 (23) 25 (23) 15 (14)
ISN regions
Africa 33 7 (21) 6 (18) 8 (24) 12 (37)
Middle East 13 5 (38) 5 (38) 3 (24) 0
Latin America 5 2 (40) 1 (20) 1 (20) 1 (20)
North and East Asia 6 1 (17) 4 (66) 1 (17) 0
South Asia 5 0 2 (40) 2 (40) 1 (20)
OSEA 13 6 (46) 3 (23) 4 (31) 0
East and Central Europe 16 11 (68) 2 (13) 2 (13) 1 (6)
NIS and Russia 6 2 (33) 1 (17) 3 (50) 0
Western Europe 9 7 (78) 1 (11) 1 (11) 0
North America 2 2 (100) 0 0 0
World Bank income groups
Low 17 2 (12) 1 (6) 3 (18) 11 (64)
Lower middle 29 5 (17) 9 (31) 13 (45) 2 (7)
Upper middle 27 10 (37) 10 (37) 5 (19) 2 (7)
High 35 26 (75) 5 (14) 4 (11) 0
(continued)
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Table 7. Availability of Services for Chronic Kidney DiseaseMonitoring andManagement at Secondary
or Tertiary Care Levels (continued)
No. of
Responding Countries
Availability, No. (%) of Responding Countries
Always Usually Rarely Never
Serum creatinine
without eGFR reporting
Overall 117 68 (58) 40 (34) 7 (6) 2 (2)
ISN regions
Africa 32 9 (28) 19 (60) 3 (9) 1 (3)
Middle East 13 13 (100) 0 0 0
Latin America 16 10 (62) 6 (38) 0 0
North and East Asia 6 3 (50) 3 (50) 0 0
South Asia 5 3 (60) 2 (40) 0 0
OSEA 12 6 (50) 5 (42) 1 (8) 0
East and Central Europe 16 12 (75) 2 (13) 1 (6) 1 (6)
NIS and Russia 6 5 (83) 1 (17) 0 0
Western Europe 9 5 (56) 2 (22) 2 (22) 0
North America 2 2 (100) 0 0 0
World Bank income groups
Low 17 2 (12) 12 (70) 2 (12) 1 (6)
Lower middle 31 16 (52) 13 (42) 2 (6) 0
Upper middle 31 24 (77) 7 (23) 0 0
High 38 26 (68) 8 (21) 3 (8) 1 (3)
UACR or UPCR Measurement
Overall 118 32 (27) 47 (40) 28 (24) 11 (9)
ISN regions
Africa 32 2 (6) 8 (25) 14 (44) 8 (25)
Middle East 13 5 (38) 8 (62) 0 0
Latin America 16 4 (25) 10 (62) 2 (13) 0
North and East Asia 6 1 (17) 4 (66) 0 1 (17)
South Asia 5 0 3 (60) 2 (40) 0
OSEA 13 4 (31) 4 (31) 5 (38) 0
East and Central Europe 16 7 (44) 4 (25) 4 (25) 1 (6)
NIS and Russia 6 1 (17) 3 (49) 1 (17) 1 (17)
Western Europe 9 6 (67) 3 (33) 0 0
North America 2 2 (100) 0 0 0
World Bank income groups
Low 17 0 1 (6) 10 (59) 6 (35)
Lower middle 33 3 (9) 15 (46) 13 (39) 2 (6)
Upper middle 30 9 (30) 14 (47) 4 (13) 3 (10)
High 38 20 (52) 17 (45) 1 (3) 0
Radiology Services (Ultrasound)
Overall 119 68 (57) 45 (38) 6 (5) 0
ISN regions
Africa 33 13 (39) 16 (49) 4 (12) 0
Middle East 13 12 (92) 1 (8) 0 0
Latin America 16 8 (50) 8 (50) 0 0
North and East Asia 6 3 (50) 3 (50) 0 0
South Asia 5 3 (60) 2 (40) 0 0
OSEA 13 5 (38) 6 (47) 2 (15) 0
East and Central Europe 16 12 (75) 4 (25) 0 0
NIS and Russia 6 4 (67) 2 (33) 0 0
Western Europe 9 6 (67) 3 (33) 0 0
North America 2 2 (100) 0 0 0
World Bank income groups
Low 17 5 (29) 9 (53) 3 (18) 0
Lower middle 33 15 (45) 16 (49) 2 (6) 0
Upper middle 31 19 (62) 11 (35) 1 (3) 0
High 38 29 (76) 9 (24) 0 0
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and AKI care were present in only a few countries, with
wide variations across regions on the reported availability
and access to care guidelines. The presence of CKD and AKI
advocacy groups was reported as limited in most regions
and was more common for AKI than for CKD, with more
than two-thirds of countries reporting absence of capacity
to participate in clinical research.
The status of kidney health care as suggested by this
study indicates that the health systems of many countries
face substantial challenges in closing the large gaps that are
reported to currently exist in meeting the health needs of
people with AKI and CKD around the world.1,19 First, the
reported limited availability of and public funding for AKI
and CKD care (kidney replacement therapy technologies,
essential medicines, service delivery and infrastructures,
kidney disease detection), particularly in low- and lower
middle–income countries, call for strategies at global,
regional, and national levels to make these care components
accessible and affordable to the burgeoning populace with
kidney disease.20-23 While community-based kidney disease
prevention, identification, and treatment programs repre-
sent an important low-cost strategy with the potential
for significant public health benefits,24,25 the present
study found that most countries reported inadequate
CKD detection and surveillance systems to achieve this
goal. For example, the ability to quantitatively measure
serum creatinine with eGFR reporting and proteinuria even
at secondary care levels was “always” possible in only 7
(21%) and 2 (6%) African countries, respectively. Further-
more, peritoneal dialysis tended to be relatively underuti-
lized in resource-poor countries, even though this mode is
generally considered a less expensive and technically less
demanding form of kidney replacement therapy26 that
is particularly suited to low- and lower–middle income
countries challenged by limited finances, limited nephrol-
ogy workforce, and geographical barriers.21 Developing low-
cost kidney disease detection programs (integrated with
other noncommunicable disease strategies) and low-cost
dialysis programs in resource-limited settings requires
building partnerships among industry, international health
agencies, and governments,22 as occurred with the estab-
lishment of low-cost chronic disease management programs
in Africa.22,27-29
A second challenge is the limited availability of re-
liable surveillance systems reported for both AKI and CKD
across countries and regions, which is a major impediment
to designing and implementing effective interventions to
close the identified gaps in infrastructures and services.30
Policy decisions at national and international levels
are required to support development of functional informa-
tion systems across the broad spectrum of kidney diseases
and to track and monitor burden, treatment, and related
outcomes.29,30
A third key challenge is the limited workforce capacity
reported in most countries and regions, especially dialysis
nurses, laboratory workers, dietitians, transplant coordina-
tors, and nephrologists. Because health care workforce avail-
ability is a prerequisite for effective AKI and CKD manage-
ment programs and policies,29 the challenge of health care
professional shortages will require a concerted response from
major national and international stakeholders.11,27
Fourth, the limited capacity reported in most regions
and countries to undertake clinical research calls for more
investment and a targeted research agenda to improve
understanding of kidney disease burden, process of care,
outcomes monitoring, and testing of novel interventions,
particularly in low- and lower middle–income countries.27
The key strengths of the GKHA Project were the de-
velopment of the study protocol and survey instrument,
which followed a well-validated conceptual framework
Table 7. Availability of Services for Chronic Kidney DiseaseMonitoring andManagement at Secondary
or Tertiary Care Levels (continued)
No. of
Responding Countries
Availability, No. (%) of Responding Countries
Always Usually Rarely Never
Pathology Services (Renal Biopsy)
Overall 118 27 (23) 47 (39) 28 (24) 16 (14)
ISN regions
Africa 32 1 (3) 6 (19) 13 (40) 12 (38)
Middle East 13 4 (31) 8 (61) 1 (8) 0
Latin America 16 2 (13) 11 (68) 2 (13) 1 (6)
North and East Asia 6 1 (17) 3 (50) 2 (33) 0
South Asia 5 0 4 (80) 1 (20) 0
OSEA 13 3 (23) 3 (23) 5 (39) 2 (15)
East and Central Europe 16 9 (56) 4 (25) 2 (13) 1 (6)
NIS and Russia 6 0 4 (67) 2 (33) 0
Western Europe 9 5 (56) 4 (44) 0 0
North America 2 2 (100) 0 0 0
World Bank income groups
Low 17 0 3 (18) 5 (29) 9 (53)
Lower middle 32 1 (3) 12 (37) 15 (47) 4 (13)
Upper middle 31 3 (10) 18 (57) 7 (23) 3 (10)
High 38 23 (60) 14 (37) 1 (3) 0
Abbreviations: eGFR, estimated
glomerular filtration rate;
ISN, International Society of
Nephrology; NIS, newly independent
states; OSEA, Oceania and
South East Asia; UACR, urine
albumin:creatinine ratio; UPCR, urine
protein:creatinine ratio.
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assessing capacity for other chronic diseases based on the
widely applied WHO health system building blocks.15
The survey had high external validity, involving 125 coun-
tries and including very good coverage across regions and
income levels. Data were reviewed for accuracy and validity
by regional and national stakeholders knowledgeable of the
local context across regions and countries. Furthermore,
the findings were corroborated and validated via triangula-
tion with secondary data sources based on a review of
published and other literature at country levels (provided
by survey respondents and other sources). In addition,
a future survey using similar methods may provide assess-
ments of improvements or declines in global kidney health
care status.
The GKHA Project and this study also have several limi-
tations. The use of a questionnaire survey, although an
important source of information, was potentially subjective
and highly dependent on the knowledge, expertise, and
perceptions of the respondents. Furthermore, there are no
internationally agreed on or recommended benchmarks for
health care workforce densities, and therefore, precise defi-
nition of what constitutes a health worker shortage is likely
Figure 2. Global Distribution of Nephrologists Per 1 Million Population
Distribution of nephrologists













Themap depicts global distribution of nephrologists per 1 million population by country and region. Data not available indicates that data were either not known or
not provided on the questionnaire for countries that received the survey.
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to vary considerably between different countries. The sur-
vey questions were limited to only face validity and were
reliant on respondents answering fairly and representing
the status of services in their country accurately. To address
these potential problems, respondents with a range of kid-
ney care knowledge, expertise, and regional representation
were carefully selected in liaison with the ISN regional
boards. There was potential for social desirability bias to
have influenced some responses, which was mitigated by
corroborating findings with regional leaders as well as sec-
ondary data sources. The study also did not take into
account some important dimensions of health systems,
such as quality, efficiency, accessibility, geographic distribu-
tion, and within-country heterogeneity (particularly
between urban and rural regions).
Conclusions
This survey demonstrated significant interregional and
intraregional variability in the current capacity for kidney
care across the world, including important gaps in services
and workforce. Assuming the responses accurately reflect
the status of kidney care in the respondent countries, these
findings may be useful to inform efforts to improve the
quality of kidney care worldwide.
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eFigure 1. Global availability of nephrology workforce 
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eFigure 1C. In your opinion, is there a shortage of any of the following care providers in your country? Overall “yes” response, %  
 
 
Total number of responding countries = 121. 
Abbreviations: GP – General practitioners; PMP – per 1 million population. 
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eFigure 2. Availability of renal registries by region, n/N (%) 
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n/N (%): n = Number of countries; N = Total countries in region 
Abbreviations: NIS – Newly Independent States; OSEA - Oceania and South East Asia 
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eFigure 3. Presence of advocacy group for kidney care, n/N (%) 
 
n/N (%): n = Number of countries; N = Total countries in region 
Abbreviations: AKI – acute kidney injury; CKD – chronic kidney disease; NIS – Newly Independent States; OSEA - Oceania and 
South East Asia 
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eTable 1. Assessment of healthcare infrastructure available for providing kidney care (n, %) 
  Infrastructure for AKI  Infrastructure for CKD  



























Overall  122 8(7) 17(14) 38(31) 48(39) 11(9) 122 4(3) 18(15) 45(37) 46(38) 9(7) 
ISN regions:              
- Africa 34 6(18) 11(32) 9(26) 8(24) 0(0) 34 4(12) 11(32) 13(38) 6(18) 0(0) 
- Middle East 13 1(8) 1(8) 4(31) 7(53) 0(0) 13 0(0) 1(8) 6(46) 6(46) 0(0) 
- Latin America 16 1(6) 2(13) 7(44) 6(37) 0(0) 16 0(0) 1(6) 7(44) 8(50) 0(0) 
- North & East Asia 6 0(0) 0(0) 2(33) 3(50) 1(17) 6 0(0) 1(17) 1(17) 3(49) 1(17) 
- South Asia 5 0(0) 0(0) 3(60) 2(40) 0(0) 5 0(0) 1(20) 2(40) 2(40) 0(0) 
- OSEA 13 0(0) 2(15) 4(31) 5(39) 2(15) 13 0(0) 2(15) 4(31) 5(39) 2(15) 
- East & Central 
Europe 
17 0(0) 0(0) 6(35) 9(53) 2(12) 17 0(0) 1(6) 7(41) 7(41) 2(12) 
- NIS & Russia 6 0(0) 1(17) 2(33) 2(33) 1(17) 6 0(0) 0(0) 4(67) 2(33) 0(0) 
- Western Europe 10 0(0) 0(0) 1(10) 6(60) 3(30) 10 0(0) 0(0) 0(0) 7(70) 3(30) 
- North America 2 0(0) 0(0) 0(0) 0(0) 2(100) 2 0(0) 0(0) 1(50) 0(0) 1(50) 
             
World Bank 
Groups:  
- Low income 17 3 (18) 6 (35) 3 (18) 5 (29) 0 (0) 17 2 (12) 5 (29) 6 (35) 4 (24) 0 (0) 
- Lower-middle 
income 
34 3 (9) 7 (21) 14 (41) 9 (26) 1 (3) 34 1 (3) 7 (21) 18 (52) 8 (24) 0 (0) 
- Upper-middle 
income 
32 2 (6) 4 (13) 13 (40) 12 (38) 1 (3) 32 1 (3) 6 (19) 15 (47) 9 (28) 1 (3) 
- High income 39 0 (0) 0 (0) 8 (21) 22 (56) 9 (23) 39 0 (0) 0 (0) 6 (15) 25 (64) 8 (21) 
Ratings were based on a Likert scale: 1 (extremely poor), 2 (poor/below average), 3 (Fair/average), 4 (good/above average), and 5 (excellent). 
Abbreviations: AKI=acute kidney injury; CKD=chronic kidney disease; NIS - Newly Independent States; OSEA - Oceania and South East Asia 
The proportion was calculated as the number of countries that choose the answer divided by the total number of responding countries.  
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Total number of responding countries 33 13 16 6 5 13 17 6 10 2 
Countries with "yes" response by provider, n (%) 
   Counselors and psychologists 27 (82) 8 (62) 7 (44) 4 (67) 4 (80) 11 (85) 11 (65) 5 (83) 4 (40) 0 (0) 
   Dialysis nurses 25 (76) 10 (77) 13 (81) 3 (50) 4 (80) 11 (85) 10 (59) 1 (17) 5 (50) 1 (50) 
   Dialysis technicians 25 (76) 6 (46) 10 (63) 4 (67) 4 (80) 11 (85) 6 (35) 2 (33) 3 (30) 1 (50) 
   Dietitians 30 (91) 10 (77) 9 (56) 5 (83) 4 (80) 12 (92) 13 (76) 6 (100) 5 (50) 0 (0) 
   GP and primary care physicians 13 (39) 3 (23) 6 (38) 3 (50) 2 (40) 5 (38) 4 (24) 1 (17) 3 (30) 1 (50) 
   Laboratory technicians 14 (42) 3 (23) 6 (38) 1 (17) 4 (80) 8 (62) 2 (12) 2 (33) 2 (20) 0 (0) 
   Nephrologists 28 (85) 11 (85) 14 (88) 4 (67) 4 (80) 11 (85) 10 (59) 4 (67) 2 (20) 1 (50) 
   Nurse practitioners 19 (58) 8 (62) 12 (75) 5 (83) 3 (60) 12 (92) 8 (47) 3 (50) 2 (20) 1 (50) 
   Pharmacists 12 (36) 6 (46) 4 (25) 1 (17) 4 (80) 5 (38) 1 (6) 0 (0) 2 (20) 1 (50) 
   Renal pathologists 33 (100) 11 (85) 16 (100) 5 (83) 4 (80) 13 (100) 11 (65) 4 (67) 7 (70) 0 (0) 
   Social workers 17 (52) 9 (69) 7 (44) 6 (100) 4 (80) 11 (85) 12 (71) 4 (67) 5 (50) 0 (0) 
   Transplant coordinators 28 (85) 10 (77) 11 (69) 4 (67) 5 (100) 12 (92) 8 (47) 4 (67) 2 (20) 0 (0) 
   Vascular access coordinators 29 (88) 9 (69) 15 (94) 6 (100) 4 (80) 12 (92) 14 (82) 4 (67) 5 (50) 0 (0) 
n = Number of countries 
Abbreviations:  GP=general practitioners; NIS= Newly Independent States 
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eTable 3. Does your country have a national strategy for improving the care of CKD patients? (n, %) 
 No. of responding 
countries  
Yes, a national CKD specific strategy 
exists  
Yes, but the CKD strategy is incorporated into a NCD strategy that includes 
other diseases  
No 
Overall  109 19 (17) 29 (27) 61 
(56) 
ISN regions:      
- Africa 26 1 (4) 7 (27) 18 
(69) 
- Middle East 13 3 (23) 2 (15) 8 (62) 
- Latin America 16 5 (31) 5 (31) 6 (38) 
- North & East Asia 6 1 (17) 3 (50) 2 (33) 
- South Asia 3 1 (33) 0 (0) 2 (67) 
- OSEA 12 4 (33) 3 (25) 5 (42) 
- East & Central 
Europe 
16 2 (13) 4 (25) 10 
(62) 
- NIS & Russia 6 0 (0) 2 (33) 4 (67) 
- Western Europe 9 2 (22) 2 (22) 5 (56) 
- North America 2 0 (0) 1 (50) 1 (50) 
     
World Bank Groups:     








29 5 (17) 10 (34) 14 
(49) 
- High income 38 8 (21) 10 (26) 20 
(53) 
Abbreviations: CKD - chronic kidney disease; NCD - Non-communicable diseases; NIS - Newly Independent States; OSEA - Oceania and South East Asia. 
 
The proportion was calculated as the number of countries that choose the answer divided by the total number of responding countries.  
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eTable 4. Does your country have a national strategy for improving the identification of AKI? Response, (n, %) 




paper on AKI  
Tools available for 
identification of AKI  
Incentives for 
quality care  
Important regional/state level 
strategy or strategies  
Increasing access to 
acute dialysis facilities  
No strategies 
exist for AKI  
Overall  116 19 (16) 37 (32) 14 (12) 12 (10) 36 (31) 59 (51) 
ISN regions:         
- Africa 30 3 (10) 8 (27) 1 (3) 2 (7) 7 (23) 18 (60) 
- Middle East 13 2 (15) 4 (31) 2 (15) 0 (0) 6 (46) 6 (46) 
- Latin 
America 
16 4 (25) 3 (19) 0 (0) 1 (6) 4 (25) 10 (63) 
- North & East 
Asia 
6 3 (50) 2 (33) 2 (33) 0 (0) 1 (17) 2 (33) 
- South Asia 5 0 (0) 3 (60) 2 (40) 2 (40) 2 (40) 1 (20) 
- OSEA 13 2 (15) 6 (46) 1 (8) 3 (23) 8 (62) 4 (31) 
- East & 
Central 
Europe 
16 1 (6) 5 (31) 4 (25) 2 (13) 5 (31) 9 (56) 
- NIS & 
Russia 
6 1 (17) 2 (33) 1 (17) 0 (0) 2 (33) 4 (67) 
- Western 
Europe 
9 3 (33) 3 (33) 1 (11) 1 (11) 1 (11) 5 (56) 
- North 
America 
2 0 (0) 1 (50) 0 (0) 1 (50) 0 (0) 0 (0) 
        
World Bank Groups:        








30 7 (23) 11 (37) 3 (10) 4 (13) 15 (50) 15 (50) 
- High income 38 9 (24) 13 (34) 6 (16) 4 (11) 9 (24) 17 (45) 
 
Abbreviations: AKI - acute kidney injury; NIS - Newly Independent States; OSEA - Oceania and South East Asia 
 
The proportion was calculated as the number of countries that choose the answer divided by the total number of responding countries.  
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eTable 5. Access to clinical practice guidelines for kidney care (n, %) 


















Overall  116 31 (27) 1 (1) 60 (52) 116 8 (7) 1 (1) 52 (45) 
ISN regions:          
- Africa 30 4 (13) 0 (0) 13 (43) 30 2 (7) 0 (0) 8 (27) 
- Middle East 13 1 (8) 1 (8) 8 (62) 13 0 (0) 0 (0) 5 (38) 
- Latin America 16 9 (56) 0 (0) 7 (44) 16 1 (6) 0 (0) 7 (44) 
- North & East Asia 6 3 (50) 0 (0) 3 (50) 6 0 (0) 0 (0) 2 (33) 
- South Asia 5 0 (0) 0 (0) 3 (60) 5 0 (0) 0 (0) 1 (20) 
- OSEA 13 6 (46) 0 (0) 2 (15) 13 2 (15) 1 (8) 3 (23) 
- East & Central Europe 16 2 (13) 0 (0) 13 (81) 16 0 (0) 0 (0) 15 (94) 
- NIS & Russia 6 1 (17) 0 (0) 5 (83) 6 2 (33) 0 (0) 3 (50) 
- Western Europe 9 4 (44) 0 (0) 5 (56) 9 1 (11) 0 (0) 6 (67) 
- North America 2 1 (50) 0 (0) 1 (50) 2 0 (0) 0 (0) 2 (100) 
         
World Bank Groups:          
- Low income 17 1 (6) 0 (0) 6 (35) 17 0 (0) 0 (0) 3 (18) 
- Lower-middle income 31 7 (23) 0 (0) 16 (52) 31 5 (16) 0 (0) 11 (35) 
- Upper-middle income 30 9 (30) 0 (0) 16 (53) 30 1 (3) 1 (3) 14 (47) 
- High income 38 14 (37) 1 (3) 22 (58) 38 2 (5) 0 (0) 24 (63) 
 
The proportion was calculated as the number of countries that choose the answer divided by the total number of responding countries.  
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eTable 6. Capacity and availability of regulatory framework for clinical research (n, %) 












































































































































































































































Overall  116 33(28) 46(40) 61(53) 62(53) 67(58) 116 52(45) 99(85) 56(48) 52 29(56) 27(52) 11(21) 106 66(62) 13(12) 41(39) 13(12) 
ISN regions:  
- Africa  30 4(13) 3(10) 5(17) 4(13) 18(60) 30 7(23) 25(83) 11(37) 8 6(75) 4(50) 0(0) 26 11(42) 4(15) 12(46) 3(12) 
- Middle East  13 1(8) 3(23) 4(31) 5(38) 9(69) 13 5(38) 10(77) 7(54) 5 1(20) 5(100) 0(0) 10 7(70) 2(20) 4(40) 0(0) 
- Latin America  16 3(19) 3(19) 9(56) 10(63) 13(81) 16 5(31) 15(94) 3(19) 6 4(67) 3(50) 1(17) 15 12(80) 1(7) 5(33) 3(20) 
- North & East Asia  6 4(67) 5(83) 5(83) 5(83) 3(50) 6 5(83) 6(100) 5(83) 6 6(100) 3(50) 1(17) 6 6(100) 1(17) 1(17) 0(0) 
- South Asia  5 3(60) 3(60) 2(40) 2(40) 0(0) 5 0(0) 5(100) 4(80) 2 1(50) 0(0) 1(50) 4 4(100) 0(0) 2(50) 0(0) 
- OSEA 13 5(38) 6(46) 7(54) 8(62) 10(77) 13 7(54) 11(85) 7(54) 7 2(29) 6(86) 3(43) 12 8(67) 0(0) 6(50) 2(17) 
- East & Central 
Europe  
16 3(19) 10(63) 14(88) 13(81) 4(25) 16 11(69) 12(75) 7(44) 8 3(38) 3(38) 2(25) 16 8(50) 1(6) 6(38) 2(13) 
- NIS & Russia  6 1(17) 2(33) 4(67) 4(67) 0(0) 6 2(33) 4(67) 1(17) 2 0(0) 1(50) 1(50) 6 3(50) 0(0) 3(50) 1(17) 
- Western Europe  9 7(78) 9(100) 9(100) 9(100) 8(89) 9 8(89) 9(100) 9(100) 6 4(67) 2(33) 1(17) 9 5(56) 3(33) 2(22) 2(22) 
- North America  2 2(100) 2(100) 2(100) 2(100) 2(100) 2 2(100) 2(100) 2(100) 2 2(100) 0(0) 1(50) 2 2(100) 1(50) 0(0) 0(0) 
World Bank Groups:  
- Low income  17 3 (18) 1 (6) 0 (0) 0 (0) 13 (76) 17 1 (6) 13 (76) 4 (24) 4 3 (75) 1 (25) 1 (25) 14 5 (36) 1 (7) 8 (57) 2 (14) 
- Lower -middle income  31 5 (16) 7 (23) 9 (29) 9 (29) 12 (39) 31 7 (23) 25 (81) 12 (39) 8 5 (63) 4 (50) 1 (13) 26 17 (65) 2 (8) 10 (38) 2 (8) 
- Upper -middle income  30 7 (23) 10 (33) 19 (63) 20 (67) 17 (57) 30 14 (47) 25 (83) 11 (37) 11 7 (64) 7 (64) 1 (9) 28 18 (64) 2 (7) 13 (46) 6 (21) 
- High income  38 18 (47) 28 (74) 33 (87) 33 (87) 25 (66) 38 30 (79) 36 (95) 29 (76) 29 14 (48) 15 (52) 8 (28) 38 26 (68) 8 (21) 10 (26) 3 (8) 
*Other forms of regulatory approval framework not in conformity with the stated ones.
Abbreviations: ISN - International Society of Nephrology; NIS - Newly Independent States; OSEA= Oceania and South East Asia 
 The proportion was calculated as the number of countries that choose the answer divided by the total number of responding countries. 
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eAppendix 1: Study questionnaire 
Global  Kidney  Health  Atlas  (GKHA) Questionnaire  
Assessing  Country  and Regional  Profile  for  Readiness,  Capacity  and Response  
to CKD and AKI  
The International Society  of  Nephrology  (ISN) plans  to  work  collaboratively  with  existing  
organizations  and initiatives  at international and  nationaal levels  - to  promote  early  detection  and 
effective  treatment  of  kidney  diseases  in  order  to  improve  patient  health  and quality  of  life.  
Through  understanding  and potentially  helping  to  shape  relevant  health  policies, practices  and 
infrastructure, ISN aims  to  facilitate  the implementation  of  equitable  and ethical care  for  kidney  
patients  in  all regions  and countries  of  the  world.  
ISN intends  to  conduct  a research  exercise  on  the current  status  of  care  for  kidney  patients  
across  all countries  of  the world. This  project  will determine  the global status  of  CKD and AKI  
care  structures  and organization  towards  achieving  universal health  care  (UHC), and devise  
policy  implications  for  including  CKD and AKI in  the global health  agenda.  
This  questionnaire  is  designed  to  address  the  6 core  areas  which  inform  aspects  of  universal  
health  coverage:  health  finance, health  workforce, essential medications  and health  products  
access, health  information  systems  and statistics, national health  policy,  and service  delivery  
and safety  as well as  the  response  of  nephrology  community  and capacity  for  research  and 
development. Using  this  framework, we  will be  able  to  develop  an appropriate  global perspective  
on the state  of  kidney  health  and disease.  
If you  have any questions  about  completing  the  questionnaire  please  contact:  Sandrine  Damster  
(email:  SDamster@theisn.org).  
Thank  you  for  your  involvement  and  readiness  to  participate.  
Dr. Adeera  Levin, MD, FRCPC, FACP 
President, International Society  of  Nephrology  
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Global  Kidney  Health  Atlas  (GKHA) Questionnaire  
Questionnaire modules: 
Standardized  questions  to  allow  comparisons  of  country  capacities  and readiness  based  on 
WHO six  domains  of  UHC, and responses  (based  on awareness, identified  barriers  and  capacity  
for  research  and development  in  nephrology  community)  
Assessing  capacity  and readiness  on  nations  for  kidney  care based  UHC domains  
1. HF - Health Finance: Funding mechanism and availability
2. SDS - Service  delivery  and safety:
a. Structure  and  organization  of  care  delivery  for  CKD
b. Structure  and  organization  of  care  delivery  for  AKI
3. HW - Health  workforce:  Essential workforce  for  CKD and AKI care
4. EMHPA - Essential medications  and  Health  products  access:  Availability,  coverage  and
access  
5. HISS - Health  information  systems  and statistics:  Databases, registries  and  surveillance
systems  
6. NHP - National health  policy:
a. CKD policy,  strategies  and frameworks  in  the context  of  existing  NCD programs
b. AKI policy,  strategies  and frameworks
Asses sing  response  of  nephrology  community  (awareness, identified  barriers  and capacity  for  
research  and  development)  
a. Awareness  and education  on CKD
b. Awareness  and education  on AKI
c. Identified  barriers  to  CKD care
d. Identified  barriers  to  AKI care
e. Capacity  for  research  and development
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Global  Kidney  Health  Atlas  (GKHA) Questionnaire  
Assessing  Country  and Regional  Profile  for  Readiness,  Capacity  and Response  to 
CKD and AKI  
CONTACT 




* Status? (please tick all that apply)
   Nephrologist    Non-nephrologist (non-physician) 
   Non-nephrologist (physician)    Administrator/policy maker 
 Other (please specify) 
* In which country do you reside?
* ISN region?
* Email contact person
Telephone (optional) contact person: 
Fax (optional) contact person: 
© 2017 American Medical Association. All rights reserved.
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Global  Kidney  Health  Atlas  (GKHA) Questionnaire  
A. Health  Finance,  Service  delivery  and Safety  
A.1. Description  of  the healthcare  system  
* A.1.1. In general, what best describes your healthcare system?
Publicly funded by government and free at the point of deliver Solely private and out-of-pocket 
Publicly funded by government but with some fees at the point Multiple systems –programs provided by government, non- 
of delivery governmental organizations (NGOs), and communities 
A mix of publicly funded (whether or not publicly funded 
component is free at point of delivery) and private systems 
(please explain) 
If a mix of publicly funded and private systems (please explain) or "Other" (please specify) 
A.1.2. If your healthcare system is publicly funded, (in whole or in part) is this coverage universal (ie: are all 
residents of your country eligible to participate?)? 
   Yes, all residents are included in the coverage 
   Not applicable: there is no publicly funded health care in my country 
 No, not all residents are included (please specify details) 
A.1.3. If your healthcare system is publicly funded (in whole or in part), which aspects of care are not 
included in the coverage? (please tick all that apply) 
Dialysis Early detection in individuals at risk 
Transplantation Management of AKI 
Management of CKD (Chronic Kidney Disease) complication None – all aspects funded 
(anemia, bone disease, malnutrition) 
Early management to reduce risk of CKD progression (risk 
factor control) 
Other (please specify) 
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*  A.1.4. What best describes your healthcare system’s coverage for care of patients with kidney disease 
(excluding medications)? 
   Publicly funded for all patients with AKI    Publicly funded for all patients living on kidney transplant only 
   Publicly funded for all patients with CKD    Solely private and out-of-pocket for all AKI patients 
   Publicly funded for all patients on Renal Replacement Therapy Solely private and out-of-pocket for all CKD patients 
(RRT) only 
   Publicly funded for all patients on dialysis only 




*  A.1.5. We are interested in understanding within-country variation in kidneycare delivery as well as 
between-country variation. In your opinion, is there important variation in the way that kidney care is 
organized or delivered between different regions/states within your country? 
Yes (if possible please 
provide brief details) 
 
No (please explain why) 
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Global  Kidney  Health  Atlas  (GKHA) Questionnaire  
 
A.2 Service  delivery  and safety:  Structure  and organization  of  care delivery  for  CKD 




*  A.2.1. What system best describes the oversight/direction of kidney disease care in your country? 
 
Managed/overseen by a national body Managed by non-governmental organizations (NGOs) 
 
Managed/overseen by provincial/regional/state level No organized system 
authorities only 
 
Managed by individual Hospitals/Trusts/Organizations 
 
Other (please specify) 
  
 
*  A.2.2. How would you rate the health infrastructure in your country, in terms of adequacy for providing 




*  A.2.3. Apart from health infrastructure, how would you rate the availability of other types of funding in 




*  A.2.4. How would you rate the health infrastructure in your country, in terms of adequacy for providing 




*  A.2.5. Apart from health infrastructure, how would you rate the availability of other types of funding in 
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Global  Kidney  Health  Atlas  (GKHA) Questionnaire  
Data sources  for  Section  A 
We would  like  you  to  consult  as many  colleagues  or  sources  of  data as needed  to  provide  the 
answers  that  best  describe  nephrology  care in  your  country.  
* What is/are the sources for the data you provided above for Section A?
* On a scale of 1-5 (1 = very uncertain, 5 = very certain) how certain are you of the answers you have
provided for Section A?
© 2017 American Medical Association. All rights reserved.
Global  Kidney  Health  Atlas  (GKHA) Questionnaire  
B. Health  workforce  for  nephrology  care  
B1. Existing  manpower  capacity  
* B.1.1. Who bears primary responsibility for the delivery of CKD care in your country (please tick all that
apply)?
Nephrologists Multidisciplinary teams 
Primary care physicians Health officers/extension workers 
Nurse practitioners or specialized nurses 
Other specialists? (please specify) 
* B.1.2. Who bears primary responsibility for the delivery of AKI care in your country (please tick all that
apply)?
   Nephrologists    Nurse practitioners or specialized nurses 
   Intensive care specialists    Health officers/extension workers 
   Primary care physicians    Technicians 
   Other specialists? (please specify) 
* B.1.3. How many nephrologists are there in your country, and how many nephrology trainees?
Nephrologists
Nephrology trainees
* B.1.4. In your opinion, is there a shortage of any of the following providers in your country (please tick
all that apply)?
   Nephrologists    Vascular Access Coordinators    Dialysis nurses 
   Dietitians    Nurse Practitioners    Dialysis technicians 
   Social workers    Counselors/Psychologists    General practitioners/primary care 
physicians 
   Pharmacists    Transplant Coordinators 
   No shortage of any of the staff 
mentioned above 
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Global  Kidney  Health  Atlas  (GKHA) Questionnaire  
B2. Training  capacity  
* B.2.1. Is there a nephrology training program in your country?
Yes 
No 
* B.2.2. How long is the training in nephrology (years)?
* B.2.3. How is the training in nephrology structured?
   Following general internal medicine    A mix of 1 & 2 depending on region and/or training centre 
 Solo training after basic qualification as medical doctor 
   Other (please specify) 
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Global  Kidney  Health  Atlas  (GKHA) Questionnaire  
Data sources  for  Section  B 
We would  like  you  consult  as many  colleagues  or  sources  of  data  as needed  to  provide  the 
answers  that  best  describe  nephrology  care in  your  country.  
* What is/are the sources for the data you provided above for Section B?
* On a scale of 1-5 (1 = very uncertain, 5 = very certain) how certain are you of the answers you have
provided for Section  B?
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C. Essential  medications  and health  products  access  
 




*  C.1.1. Indicate the availability of the following services for CKD monitoring and management at 
PRIMARY care level in your country; where: If generally available = >50% of healthcare facilities; if 
generally not available = <50% of healthcare facilities 
 





Height and weight 
measures to calculate                                                                                         




HbA1C test                                                                                         
























creatinine ratio (ACR) 
or protein: creatinine 
(PCR) measurements 
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*  C.1.2. Indicate the availability of the following services for CKD monitoring and management at 
SECONDARY OR TERTIARY care level in your country; where: Generally available = >50% of 
healthcare facilities; if generally not available = <50% of healthcare facilities 
 
Available Not Available 
 
 
Height and weight 
measures to calculate                                                                                         
                                                                                                                               body mass index 
 
 









Renal biopsy                                                                                          
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*  C.2.1 Is chronic hemodialysis available in your country? 
 
    
Yes    
No 
 
C.2.1.1 If yes, how is chronic hemodialysis funded in your country? 
 
   Publicly funded by government and free at the point of delivery 
   Publicly funded by government but with some fees at the point of delivery 
   A mix of publicly funded (whether or not publicly funded component is free at point of delivery) and private systems (please 
explain) 
 
   Solely private and out-of-pocket 
   Multiple funding sources – government, non-governmental organizations (NGOs), and communities 









C.2.2.1 If yes, how is chronic peritoneal dialysis funded in your country? 
 
   Publicly funded by government and free at the point of    Solely private and out-of-pocket 
delivery 
   Multiple funding sources – government, non-governmental 
   Publicly funded by government but with some fees at the organizations (NGOs), and communities 
point of delivery 
 
   A mix of publicly funded (whether or not publicly funded 
component is free at point of delivery) and private systems 
(please explain) 
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C.2.3.1 If yes, how is kidney transplantation funded in your country? 
 
   Publicly funded by government and free at the point of    
delivery 
 
   Publicly funded by government but with some fees at the 
point of delivery 
 
   A mix of publicly funded (whether or not publicly funded 
component is free at point of delivery) and private systems 
(please explain) 
Solely private and out-of-pocket 
 
Multiple funding sources – government, non-governmental 
organizations (NGOs), and communities 
 
If a mix of publicly funded and private systems (please explain) or "Other" (please specify) 
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Global  Kidney  Health  Atlas  (GKHA) Questionnaire  
 








C.3.1.1 If yes, how is acute hemodialysis funded in your country? 
 
   Publicly funded by government and free at the point of    Solely private and out-of-pocket 
delivery 
   Multiple funding sources – government, non-governmental 
   Publicly funded by government but with some fees at the organizations (NGOs), and communities 
point of delivery 
 
   A mix of publicly funded and private systems (please 
explain) 
 









C.3.2.1 If yes, how is acute peritoneal dialysis funded in your country? 
 
   Publicly funded by government and free at the point of    Solely private and out-of-pocket 
delivery 
   Multiple funding sources – government, non-governmental 
   Publicly funded by government but with some fees at the organizations (NGOs), and communities 
point of delivery 
 
   A mix of publicly funded (whether or not publicly funded 
component is free at point of delivery) and private systems 
(please explain) 
 
If a mix of publicly funded and private systems (please explain) or "Other" (please specify) 
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Global  Kidney  Health  Atlas  (GKHA) Questionnaire  
 




*  C.4.1 For all CKD patients: How are medications funded? 
 
   Publicly funded by government and free at the point of    Solely private and out-of-pocket 
delivery 
   Multiple funding sources – government, non-governmental 
   Publicly funded by government but with some fees at the organizations (NGOs), and communities 
point of delivery 
 
   A mix of publicly funded (whether or not publicly funded 
component is free at point of delivery) and private systems 
(please explain) 
 





*  C.4.2 For all dialysis patients: How are medications funded? 
 
   Publicly funded by government and free at the point of    Solely private and out-of-pocket 
delivery 
   Multiple funding sources – government, non-governmental 
   Publicly funded by government but with some fees at the organizations (NGOs), and communities 
point of delivery 
 
   A mix of publicly funded and private systems (please 
explain) 
 





*  C.4.3 For all transplant patients: How are medications funded? 
 
   Publicly funded by government and free at the point of    Solely private and out-of-pocket 
delivery 
   Multiple funding sources – government, non-governmental 
   Publicly funded by government but with some fees at the organizations (NGOs), and communities 
point of delivery 
 
   A mix of publicly funded and private systems (please 
explain) 
 
If a mix of publicly funded and private systems (please explain) or "Other" (please specify) 
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Data sources  for  Section  C 
 
 
We would  like  you  to  consult  as many  colleagues  or  sources  of  data as needed  to  provide  the 
answers  that  best  describe  nephrology  care in  your  country.  
 




*  On a scale of 1-5 (1 = very uncertain, 5 = very certain) how certain are you of the answers you have 
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Global  Kidney  Health  Atlas  (GKHA) Questionnaire  
 
D. Health  information  systems  & statistics  
 




*  D.1.1. Is there an ‘official’ registry in your country for? 
I don’t know-Information not 




Dialysis                                                                                                                                                 
Transplantation 
AKI                                                                                                                  
 
 
D.1.1.1. If yes [CKD], how is the registry run? 
 
   Voluntary 
   Mandatory 
   I don’t know/Information not available 
 
 
D.1.1.2. If there is a CKD registry for patients who do not require RRT, what does this registry cover 
(please tick all that apply)? 
   The whole spectrum of CKD (Stages 1-5) 
   Advanced CKD only (Stages 4/5) 
   The whole country 




D.1.1.3. If yes [Dialysis], how is the registry run? 
 
   Voluntary 
   Mandatory 
   I don’t know/Information not available 
 
 
D.1.1.4. If yes [Transplantation], how is the registry run? 
 
   Voluntary 
   Mandatory 
   I don’t know/Information not available 
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D.1.1.5. If yes [AKI], how is the registry run? 
 
   Voluntary 
   Mandatory 
I don’t know/Information not available 
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Global  Kidney  Health  Atlas  (GKHA) Questionnaire  
 




*  D.2.1. Are there data on the prevalence of CKD in your country? 
 
    
Yes    
No 
 
D.2.1.1. If yes there are data on the prevalence of CKD in my country, please provide figures if 
known. Please enter NA for "not available" figures 












With a kidney transplant 
 
 
*  D.2.2. Are there data on the incidence of CKD in your country? 
 
    
Yes    
No 
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D.2.2.1. If yes there are data on the incidence of CKD in my country, please provide figures if 
known. Please enter NA for "not available" figures 
 
















With a kidney transplant 
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*  D.3.1. For which of the following high-risk groups do practitioners in your country routinely offer testing 
for CKD? 
   Those with hypertension    Those with urological disorders (structural, stone diseases) 
   Those with diabetes    Chronic users of nephrotoxic medications 
   Those with cardiovascular disease (Ischaemic heart    Members of high-risk ethnic groups (Aboriginal, Africans, 
disease, stroke, PVD, heart failure)  Indo-asians) 
 
   Those with autoimmune/multisystem diseases (SLE,    Those with a family history of CKD 
Rheumatoid arthritis) 
 
   The elderly 
 
 
*  D.3.2. In your country, are there ethnic groups considered to be at increased risk for CKD? 
 
   No 




*  D.3.3. In your country, is there an active CKD detection program based on national policy and/or 
guidelines? 
    
Yes    
No 
 
C.3.3.1. If yes, how is this program implemented (please tick all that apply)? 
 
   Reactive approach - cases managed as identified through     Active screening of population at-risk through specific 
practice screening processes 
 
   Active screening of population at-risk through routine health 
encounters 
 
   Other (please specify) 
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Global  Kidney  Health  Atlas  (GKHA) Questionnaire  
 




*  D.4.1. Does your country have the ability to determine the prevalence of AKI not requiring dialysis? 
 
   Yes    Don’t know/info not available 
   No 
 
 
*  D.4.2. Does your country have the ability to determine the incidence of AKI not requiring dialysis? 
 
   Yes    Don’t know/info not available 
   No 
 
 
*  D.4.3. Does your country have the ability to determine the prevalence of AKI requiring dialysis? 
 
   Yes    Don’t know/info not available 
   No 
 
 
*  D.4.4. Does your country have the ability to determine the incidence of AKI not requiring dialysis? 
 
   Yes    Don’t know/info not available 
   No 
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Global  Kidney  Health  Atlas  (GKHA) Questionnaire  
 




*  D.5.1. In your country, are there specific groups considered to be at increased risk for AKI? 
 
   No 




*  D.5.2. In your country, is there an active AKI detection program based on national policy and/or 
guidelines? 
   Yes    No 
 
 
D.5.2.1. If yes, how is this program implemented (please tick all that apply)? 
 
   Reactive approach- cases managed as identified through      Active screening of population at-risk through specific 
practice screening processes 
 
   Active screening of population at-risk through routine health 
encounters 
 
   Other (please specify) 
© 2017 American Medical Association. All rights reserved.
 
 
Global  Kidney  Health  Atlas  (GKHA) Questionnaire  
 
Data sources  for  Section  D 
 
 
We would  like  you  to  consult  as many  colleagues  or  sources  of  data as needed  to  provide  the 
answers  that  best  describe  nephrology  care in  your  country.  
 




*  On a scale of 1-5 (1 = very uncertain, 5 = very certain) how certain are you of the answers you have 
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Global  Kidney  Health  Atlas  (GKHA) Questionnaire  
 
E. National  Health  Policy  
 




*  E.1.1. In your opinion, is CKD recognized as a health priority by the government in your country? 
Yes (please provide 
details) 
 
No (please explain why) 
 
 
*  E.1.2. Is there an advocacy group at the higher levels of government (ie: a Parliamentary committee) or 
an NGO to raise the profile of CKD and its prevention? 
   Yes (please provide details) 
   No (please explain why) 
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Global  Kidney  Health  Atlas  (GKHA) Questionnaire  
 




*  E.2.1. Is there an advocacy group at the higher levels of government (ie: a Parliamentary committee) or 
an NGO to raise the profile of AKI and its prevention? 
Yes (please provide 
details) 
 
No (please explain why) 
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Global  Kidney  Health  Atlas  (GKHA) Questionnaire  
 




*  E.3.1. Does your country have a national noncommunicable chronic disease strategy? 
Yes (please provide 
details) 
 
Yes, under development 
(please provide details) 
 
No (not detail needed) 
 
 
*  E.3.2. Does your country have a national strategy for improving the care of CKD patients? 
 
Non-dialysis dependent CKD Kidney transplantation Chronic dialysis 
 
Yes, a national CKD- 
specific strategy exists 
for the following 
populations (please tick 
all that apply): 
 
Yes, but the CKD 
strategy is incorporated 
into a NCD strategy that 
includes other diseases. 
The CKD strategy 
applies to the following 
populations (please tick 






*  E.3.3. If your country does not have a national strategy for improving the care of CKD patients, are 
there other initiatives that identify CKD as a health care priority in your country (please tick all that 
apply)? 
   National position paper on CKD care    Incentives for providing quality care to CKD patients 
   Provider incentives for identifying CKD    Important regional/state level strategy or strategies (please 
provide details) 
 
   If Important regional/state level strategy or strategies or Other (please specify) 
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*  E.4.1. Are there available CKD management & referral guidelines in your country? 
 
   Yes, national guidelines    Yes, uses or adopt the existing international guidelines (eg 
KDIGO) 
   Yes, major regional guidelines 
   No 
 
 
E.4.1.1. If yes, what do these management & referral guidelines cover (please tick all that apply)? 
 
   Identification of CKD Progression    Risk factor management 
   Timing and Urgency for Nephrology Referral    Management of Complications (Cardiovascular Disease, 
Hematologic and Bone disorders, Malnutrition) 
   Multidisciplinary Care Approach 
 
 
E.4.1.2. If ticked “yes” above: On a scale of 1 to 5, please rate the awareness of the CKD guideline 




E.4.1.3. If ticked “yes” above: On a scale of 1 to 5, please rate the adoption (application in clinical 




E.4.1.4. If ticked “yes” above: On a scale of 1 to 5, please rate the awareness of the CKD guideline 




E.4.1.5. If ticked “yes” above: On a scale of 1 to 5, please rate the adoption (application in clinical 
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*  E.5.1. Does your country have a national strategy for improving the identification of AKI, are there other 
initiatives that identify AKI as an important health care priority in your country (please tick all that 
apply)? 
   National position paper on AKI identification and care    Important regional/state level strategy or strategies (please 
provide details) 
   Tools available for identification of AKI 
   Increasing access to acute dialysis facilities 
   Incentives for providing quality care to AKI patients 
   No strategies exist for AKI 




*  Additional details on important regional/state level strategy or strategies important regional/state level 
strategy or strategies (5 lines): 
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*  E.6.1. Are there AKI management & referral guidelines in your country? 
 
   Yes, national guidelines    Yes, uses or adopt the existing international guidelines (eg 
KDIGO) 
   Yes, major regional guidelines 
   No 
 
 
E.6.1.1. If yes, what do these management & referral guidelines cover (please tick all that apply)? 
 
   Identification of AKI in outpatient settings    Access to dialysis treatment(s) 
   Identification of AKI in  in-patient settings    Protocols for mitigating risk of AKI in specific situations? 
   Timing and Urgency for Nephrology Referral 
 
E.6.1.2. If ticked “yes” above: On a scale of 1 to 5, please rate the awareness of the AKI management 




E.6.1.3. If ticked “yes” above: On a scale of 1 to 5, please rate the ADOPTION (application in clinical 





E.6.1.4. If ticked “yes” above: On a scale of 1 to 5, please rate the awareness of the AKI management 




E.6.1.5. If ticked “yes” above: On a scale of 1 to 5, please rate the ADOPTION (application in clinical 
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Data sources  for  Section  E 
 
 
We would  like  you  to  consult  as many  colleagues  or  sources  of  data as needed  to  provide  the 
answers  that  best  describe  nephrology  care in  your  country.  
 




*  On a scale of 1-5 (1 = very uncertain, 5 = very certain) how certain are you of the answers you have 
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Assessing  response  of  nephrology  community:  awareness,  identified  barriers  and 
capacity  for  research  
 
 
° Awareness  and education  about  CKD 
° Awareness  and education  about  AKI  
° Identified  barriers  to  kidney  disease  care  
° Capacity  for  research  and development  
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*  1.2. On a scale of 1-5 (1=poor, 5=excellent). Please rate the typical level of CKD awareness among 
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*  2.2. On a scale of 1-5 (1=poor, 5=excellent). Please rate the typical level of AKI awareness among 
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*  3.1. Barriers to optimal kidney disease care: Are there specific barriers to optimal kidney disease care in 
your country (please tick all that apply)? 
   Geography (distance from care or prolonged travel time)    Number of nephrologists per capita 
   Physician (availability, access, knowledge, attitude)    Healthcare system (availability, access, capability) 
   Patient (knowledge, attitude)    Other 
 
*  3.2 Barriers to optimal RRT provision: Are there specific barriers to optimal RRT care in your country 
(please tick all that apply)? 
   Geography (distance from care or prolonged travel time)    Number of nephrologists per capita 
   Physician (availability, access, knowledge, attitude)    Healthcare system (availability, access, capability) 
   Patient (knowledge, attitude) 
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*  4.1. Is there a national agency responsible for funding clinical trials in your country? 
 
   Yes    No 
 
 
*  4.2. Does your country participate in clinical trials in kidney disease? (Tick all that apply) 
 
   Phase 1    Phase 4 
   Phase 2    Health service delivery trials 
   Phase 3 
 
 
*  4.3. Does your country have formal training for physicians in clinical trial conduct? 
 
   Yes    Don’t know/info not available 
   No 
 
 
4.3.1. If yes, is it mandatory? 
 
   Yes    Don’t know/info not available 
   No 
 
 
*  4.4. Does your country have formal training for non-physicians/ research assistants and associates in 
clinical trial conduct? 
   Yes    Don’t know/info not available 
   No 
 
 
4.4.1. If yes, is it mandatory? 
 
   Yes    Don’t know/info not available 
   No 
 
 
*  4.5. Does your country have biobanking facilities? 
 
   Yes    Don’t know/info not available 
   No 
 
 
*  4.6. Does your country have the capacity (trained workforce) to conduct observational cohort studies? 
 
   Yes    Don’t know/info not available 
   No 
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*  4.7. Does your country usually have resources (funding) to conduct observational cohort studies? 
 




Don’t know/info not available 
 
*  4.8. Is your country involved in any observational cohort studies in CKD? 
 




Don’t know/info not available 
 
4.8.1. If yes, where? 
 
   In non dialysis CKD populations 
In dialysis populations 
In transplant populations 
 
*  4.9. Is Ethical approval in your country mandatory for observational cohort studies in CKD? 
 




Don’t know/info not available 
 
*  4.9.1. If yes, is the Ethical approval 
 









*  4.11. Are there challenges in getting timely regulatory approvals in your country? 
 
   Often 
Sometimes 
   Occasionally 
No 
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*  4.12. Are there academic centres that co-ordinate and monitor sites involved in renal clinical trials in 
your country? 
 












*  4.13. In what proportion of sites in your country is there capacity for storing clinical trial medications? 
 
   All 
   Most 
Some 
   Few 
   None 
Unknown 
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Global  Kidney  Health  Atlas  (GKHA) Questionnaire  
 
Definition  of  Terms  
 
 
Action  plan:  A scheme  of  course  of  action, which  may correspond  to  a policy  or  strategy,  with  
defined  activities  indicating  who  does  what  (type  of  activities  and people  responsible  for  
implementation), when  (time  frame), how  and with  what  resources  to  accomplish  an objective  
AKI or  CKD care.  
 
Appropriate  referral and  management:  Availability  of  an organized  system  and/or  structures  to  
ensure  that  people  with  CKD who  may benefit  from  specialist  care  are referred  for  specialist  
assessment  appropriately.  
 
Capacity:  The ability  to  perform  appropriate  tasks  effectively,  efficiently  and  sustainably.  
 
Guidelines:  A recommended  evidence -based  course  of  action  for  prevention  and/or  management  
of  AKI or  CKD. 
 
Identification  and  early  detectio n: Availability  of  an organized  system  and/or  structures  for 
identification  of  people  with  risk  factors  for  CKD (hypertension, diabetes, cardiovascular  
diseases  [ischemic  heart  disease, heart  failure, peripheral vascular  disease  and stroke],  
urological problems  [structural renal tract  disease, kidney  stones, prostatic  disorders],  
multisystem  diseases  (systemic  lupus  erythematosus,  rheumatoid  arthritis, infective  
endocarditis,etc)  family  history  of  kidney  disease.  
 
Identification:  Measures  preformed  in  at-risk  population  in  order  to  identify  individuals  who  have 
risk  factor  or  early  stages  of  disease, but  do not  yet  have symptoms.  
 
Monitoring  of  complications, risk  factor  control and  disease  progressio n: Availability  of  an 
organized  system  and/or  structures  to  ensure  that  people  with  established  CKD are:  
 
NGO: Nongovernmental organization  
 
Noncommunicable  diseases  (NCDs):  Cardiovascular  diseases  (like  heart  attacks  and  stroke),  
cancers, chronic  respiratory  diseases  (such  as chronic  obstructed  pulmonary  disease  and 
asthma)  and  diabetes.  
 
Policy:  A specific  official decision  or  set  of  decisions  designed  to  carry  out  a course  of  action 
endorsed  by a government  body,  including  a set  of  goals, priorities  and main  directions  for  
attaining  these  goals. The  policy  document  may include  a strategy  to  give  effect  to  the policy.  
 
Programs:  A planned  set  of  activities  or  procedures  directed  at a specific  purpose.  
Registry:  A systematic  collection  of  data about  CKD or  AKI.  
RRT availability:  Availability  of  an organized  system  and/or  structures  deliver  dialysis  and/or  
kidney  transplant  when  and where  needed:  
© 2017 American Medical Association. All rights reserved.
Standard care plan: Availability of an organized system and/or structures to ensure that people with 
CKD have a current agreed care plan appropriate to the stage and  rate of progression of CKD. This 
means those with early stages are being monitored appro priately at the primary care level and those 
in need of specialist care have access to it.  
Strategy: a long term plan designed to achieve a particular g oal for AKI or CKD care.  
Under development: Something which is still being devel oped or finalized and is not yet being 
implemented in the country.  
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Global  Kidney  Health  Atlas  (GKHA) Questionnaire  
THANK YOU 
Thank  you  very  much  for  taking  the  time  to  respond  to  this  survey!  
Your  active  participation  in  helping  ISN develop  an appropriate  global perspective  on the  state  of  
kidney  health  and disease  is  greatly  appreciated.  
The Global Kidney  Disease  Atlas  (GKHA)  Questionnaire  team  
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eAppendix 2. Access to RRT, medication funding and workforce capacity 
Green and red boxes indicate that the survey participants answered Y s and No, respectively. Grey boxes indicate no data were 
provided. 
Universal coverage for RRT refers to publicly funded by the government and free at the point of delivery.  
Availability of PD (peritoneal dialysis) and Tx (transplantation) refers to the availability of chronic peritoneal dialysis and 
transplantation.  
Adequacy of workforce component: is No if the respondent reported a national shortage of health care providers of the specified 
type, and Yes otherwise.  
Funding for CKD medications component refers to medication funding for non-dialysis dependent chronic kidney disease.  
Abbreviations: CKD = chronic kidney disease, RRT = renal replacement therapy, NIS & Russia= Newly Independent States and 
Russia.  
Pub Free = publicly funded by government and free at the point of delivery, Pub $ = publicly funded by government but with 
some fees at the point of delivery, Mix PP = a mix of publicly funded (whether or not publicly funded component is free at point 
of delivery) and private systems, Priv OOP = solely private and out-of-pocket, Priv HI = solely private through health insurance 
providers,  Multi Sys = multiple systems – programs provided by government, nongovernmental organizations, and communities.  
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United Arab Emirates 
West Bank & Gaza 
Yemen 





















Universal coverage for RRT 
Availability 
of PD and 
Tx 















































































































































































































































© 2017 American Medical Association. All rights reserved.  
eAppendix 3. Services for CKD care, information systems, advocacy structures, and capacity for clinical trials 
Green and red boxes indicate that the survey participants answered Y s and No, respectively. Grey boxes indicate no data were 
provided. 
*Advocacy group refers to the presence of a mechanism at the higher levels of government or a non-governmental organization to
raise the profile of the condition and its prevention. 
Abbreviations: AKI = acute kidney injury, CKD = chronic kidney disease, GFR = estimated glomerular filtration rate, UACR = 
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